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Abstract 
Growth hormone (GH) is a 22 kD, 191-aa, pituitary-derived peptide hormone 
that is essential for postnatal growth. GH signals via binding to GH receptor 
(GHR), which initiates intracellular signal transduction pathways. This leads to 
activation of target genes, most importantly the one encoding insulin-like growth 
factor (IGF)-1, which mediates most GH action.  
In this study a novel GH mutant, Δ188-190, was characterized along with previ-
ously reported GH mutants R77C and D112G. All of these mutants had been 
identified in heterozygous form in patients with retarded growth. Based on pa-
tient data, Δ188-190 was thought to be a GHR antagonist. Moreover, the ex-
tremely conserved C-terminal disulfide bridge of GH was disrupted in mutant 
Δ188-190 and its role was studied by substituting one or both of the involved 
cysteines with alanines.  
All mutants and wild type (wt) GH were produced in human embryonic kidney 
(HEK)-293 cells and an array of in vitro experiments was established for their 
characterization. It turned out that the novel Δ188-190 mutant is not a GHR an-
tagonist after all. It has a diminished binding affinity to GHR, low biological ac-
tivity and high stability compared to wt GH. R77C and D112G are rather similar 
to wt GH. The disulfide bridge is important for receptor binding and biological 
activity of GH. If one of the cysteines is removed the stability of the molecule 
drops but this can be reversed by removing both cysteines.  
If further GH mutants are to be identified, the established array of experi-
ments will be useful for their fast characterization and could even contrib-
ute to correct treatment of patients. 
growth hormone (GH) – short stature – GH-1 gene – GHR antagonist – disulfide bridge 
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Deutsche Zusammenfassung 
Wachstumshormon (GH) besteht aus 191 Aminosäuren, hat eine Molekülmasse 
von 22kD und ist essentiell für postnatales Wachstum. Es wird aus der 
Adenohypophyse freigesetzt. GH bindet an einen GH-Rezeptor (GHR) und akti-
viert somit über intrazelluläre Signalvorgänge Zielgene, insbesondere das, wel-
ches für die Kodierung von insulin-like growth factor (IGF-1) zuständig ist. IGF-1 
vermittelt den Großteil aller GH-Signale. 
Zusammen mit den bereits bekannten GH Mutanten R77C und D112G ist in die-
ser Studie der neue GH Mutant Δ188-190 charakterisiert worden. Alle drei Mu-
tanten wurden in heterozygoter Form in kleinwüchsigen Patienten identifiziert. 
Diesen Patientendaten zu Folge schien es möglich, dass Δ188-190 eine GH-
antagonistische Wirkung besitzt. Zusätzlich wurde die extrem konservierte C-
terminale Disulfidbrücke des GH im Mutanten Δ188-190 unterbrochen vorge-
funden. Die Auswirkung der Unterbrechung wurde durch Substitution einer 
oder beider involvierter Cysteine durch Alanine untersucht. 
Alle Mutanten und Wildtypen des GH wurden in menschlichen embryonalen 
Nierenzellen (HEK-293) angezüchtet und eine Reihe von in vitro Experimenten 
sind für deren Charakterisierung etabliert worden. Es zeigte sich, dass Δ188-190 
keine GH-antagonistische Wirkung besitzt. Im Vergleich zum Wildtyp weist der 
Mutant eine verminderte Bindungsaffinität zu GH, schwächere biologische Akti-
vität und höhere Stabilität auf. R77C und D112G sind dem Wildtyp GH sehr ähn-
lich. Die Disulfidbrücke ist wichtig für die Rezeptorbindung und für die biologi-
sche Aktivität von GH. Wenn ein Cystein entfernt wird vermindert sich die 
Stabilität des Moleküls. Dieser Effekt kann durch Entfernen des zweiten Cysteins 
wieder rückgängig gemacht werden.  
Die in dieser Studie etablierten Experimente können Verwendung finden in der 
Charakterisierung bislang nicht bekannter GH Mutanten und können darüber 
hinaus zur Behandlung von Patienten eingesetzt werden. 
Wachstumshormon (GH) – Kleinwuchs – GH-1 – GHR Antagonist – Disulfidbrücke  
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1 Introduction 
1.1 Growth hormone 
1.1.1 A glance to the past  
The most important events in the history of growth hormone are summa-
rised in figure 1. First observation of a growth promoting effect of pitui-
tary extract was reported in the 1920s [Evans, 1922]. It took more than 20 
years for the substance to be isolated and designated as pituitary growth 
hormone [Li, 1944]. Pituitary-derived growth hormone had successfully 
been used in treatment of pituitary dwarfism already in the 1960s [Prader, 
1964; Tanner, 1967] but the expression of growth hormone in bacteria in 
1979 took growth hormone therapy to a new level [Martial, 1979].  
 
Figure 1: Growth hormone time line. Here are summarized the most important steps in growth 
hormone research, starting from discovery of a hypophyseal growth promoting substance in 1922. 
In 1987, growth hormone receptor was purified and recombinantly ex-
pressed, and growth hormone binding protein was identified as its ex-
tracellular domain [Leung, 1987]. In the same year growth hormone was 
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for the first time crystallized [Abdel-Meguid, 1987]. In 1990 Chen et al. 
reported a growth hormone receptor antagonist, which nowadays is used 
as medication for acromegaly [Chen, 1990]. Crystal structure of the 1:2 
complex formed by growth hormone and its binding protein was revealed 
in 1992 [de Vos, 1992]. 
1.1.2 Gene locus 
The human growth hormone (hGH) gene cluster (see figure 2) on chromo-
some 17 (q22-24) contains the genes of normal pituitary-derived GH (GH-
N or GH-1), its placental variant (GH-V) and three placental lactogens 
(PLs): products of CS-A and CS-B have the same amino acid sequence, CS-
L encodes a shorter variant but a final product is not yielded. PLs are also 
known as chorionic somatomammotropins (CSs). GH-1 is expressed 
mainly in the anterior pituitary whereas the others are expressed in pla-
centa during gestation [Chen, 1989]. The differential expression is 
achieved via distinct locus control region (LCR) elements and epigenetic 
regulation [Ho, 2004]. 
 
Figure 2: The GH gene cluster. Five genes are included in the GH gene cluster: GH-N (also known 
as GH-1) for pituitary GH, GH-V for placental GH and CS-A, C-SB and CS-L for placental lactogens. 
Blue colour refers to placenta and red to pituitary. There are five LCR elements regulating the 
expression of the GH gene cluster. Two of them (I and II) are pituitary-specific, one is placenta-
specific (IV) and two operate in both tissues (III and V). In addition to the distinct LCR elements, 
also epigenetic regulation contributes to tissue-specific expression. CD79B and SCN4A are only 
included because the control region spans over them. CD79B encodes a sodium channel and 
SCN4A a B-cell receptor subunit. The figure was modified from Ho, 2004.  
1 Introduction 
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1.1.3 Structure  
Mature hGH is a 22 kD protein consisting of 191 amino acids. There are 
several molecular forms of GH in addition to the predominating 22 kD GH 
(see chapter 1.1.4.1). The 191 amino acids are organised as an antiparallel 
four-helix bundle in an up-up-down-down manner, which is more rare 
than the simple up-down-up-down topology. Helices I (L6-Y35) and IV 
(A155-S184) are somewhat longer than helices II (N72-A98) and III (D107-
R127) [Chantalat, 1995; de Vos, 1992; Sundström, 1996]. P89 causes a kink 
in helix II but this cannot be seen in the projection in figure 3.  
 
Figure 3: A hGH molecule. 22 kD hGH is a four-helix bundle with two disulfide bridges, which 
form the C-terminal small loop and the large loop between helix IV and the crossover connection 
between helices I and II. Even though it is not evident in this 3D model, the “top” of helix II start-
ing from P89 is in reality also an α-helix, as indicated by the colouring. RasMol was used for mo-
lecular modelling. PDB ID of this crystal structure is 1HGU [Chantalat, 1995] but the helices are 
coloured based on two models of GH in complex with its binding protein (GHBP), namely 3HHR 
and 1HWG [de Vos, 1992; Sundström, 1996]. 
As can be expected from the up-up-down-down topology, the connecting 
loops between helices I & II and III & IV are much longer than the one be-
tween helices II & III. Even the connecting loops contain helical segments. 
The structure is stabilised by two disulfide bridges. The one between C53 
and C165 links the so called large loop from the crossover connection be-
1 Introduction 
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tween helices I and II to helix IV. The other disulfide bridge links the small 
loop between helix IV and C-terminus via C182 and C189 [Chantalat, 1995; 
de Vos, 1992; Sundström, 1996]. Abbreviations and structures of amino 
acids are listed in appendix I. Disulfide bridges will be covered in detail in 
chapter 1.2.  
1.1.3.1 Relatives 
GH belongs to a polypeptide hormone family, whose other members in 
humans are PLs and prolactin (PRL). GH family belongs to the large 
group of hematopoietic cytokines, which are all four-helix bundles with 
the special up-up-down-down topology, and bind in a similar manner to 
hematopoietic receptors. Other hematopoietic cytokines include many in-
terleukins, erythropoietin and ciliary neurotrophic factor.  
Unlike genes of the other GH family members, which are included in the 
GH gene cluster on chromosome 17, the PRL gene is located on chromo-
some 6 (p22.2-p21.3). Therefore it is not surprising that hPRL shares the 
lowest sequence identity with hGH, 24%. Placental hGH is 93% and hPL 
(the longer variant) 86% identical to pituitary GH. Human and bovine GH 
have 66% identity. Sequences and the conserved amino acids are presented 
in table 1. Sequences were obtained from SwissProt and analysed with 
FASTA sequence comparison tool. It is believed that GH, PLs and PRL 
have a common ancestor, from which PRL diverged already 400 million 
years ago, whereas GH and PLs diverged only 10 million years ago 
[Cooke, 1981; Goffin, 1996]. Cow and man on the other hand diverged ap-
proximately 75 million years ago [Forsyth, 2002]. 
There is some degree of cross-reactivity between the hormones of the GH 
family and those of different species. For instance, non-primate GH is not 
active in human but human GH is active in non-primates [Forsyth, 2007]. 
1 Introduction 
 5 
Primate GH can also bind and activate primate PRL receptor but not vice 
versa [Teilum, 2005].  
Table 1: Conservation of GH in relatives and between species. Same amino acid is coloured yellow, a 
similar one turquoise. Cysteines forming the disulfide bridges of hGH are underlined. Sequences 
were obtained from SwissProt and aligned and compared with FASTA. 
hGH 
hGH-V 
hPL 
bGH 
hPRL 
         FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQ      
         FPTIPLSRLFDNAMLRARRLYQLAYDTYQEFEEAYILKEQKYSFLQNPQ 
         VQTVPLSRLFDHAMLQAHRAHQLAIDTYQEFEETYIPKDQKYSFLHDSQ 
        AFPAMSLSGLFANAVLRAQHLHQLAADTFKEFERTYIPEGQRYS-IQNTQ 
LPICPGGAARCQVTLRDLFDRAVVLSHYIHNLSSEMFSEFDKRYT---HGRGFITKAI 
hGH 
hGH-V 
hPL 
bGH 
hPRL 
TSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFL----RSVFANSLVY                 
TSLCFSESIPTPSNRVKTQQKSNLELLRISLLLIQSWLEPVQLL----RSVFANSLVY 
TSFCFSDSIPTPSNMEETQQKSNLELLRISLLLIESWLEPVRFL----RSMFANNLVY 
VAFCFSETIPAPTGKNEAQQKSDLELLRISLLLIQSWLGPLQFL----SRVFTNSLVF 
NS-CHTSSLATPEDKEQAQQMNQKDFLSLIVSILRSWNEPLYHLVTEVRGMQEAPEAI 
hGH 
hGH-V 
hPL 
bGH 
hPRL 
GASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDA--LLKN 
GASDSNVYRHLKDLEEGIQTLMWRLEDGSPRTGQIFNQSYSKFDTKSHNDDA--LLKN 
DTSDSDDYHLLKDLEEGIQTLMGRLEDGSRRTGQILKQTYSKFDTNSHNHDA--LLKN 
GTSDR-VYEKLKDLEEGILALMRELEDGTPRAGQILKQTYDKFDTNMRSDDA--LLKN 
LSKAVEIEEQTKRLLEGMELIVSQVHPET-KENEIYP-VWSGLPSLQMADEESRLSAY 
hGH 
hGH-V 
hPL 
bGH 
hPRL 
YGLLYCFRKDMDKVETFLRIVQCRSV-EGS-CGF 
YGLLYCFRKDMDKVETFLRIVQCRSV-EGS-CGF 
YGLLYCFRKDMDKVETFLRMVQCRSV-EGS-CGF 
YGLLSCFRKDLHKTETYLRVMKCRRFGEAS-CAF 
YNLLHCLRRDSHKIDNYLKLLKCRII-HNNNC 
 
In the following chapters, unless otherwise stated, GH refers to human pituitary 
growth hormone. 
1.1.4 Biosynthesis 
Practically all GH in circulation is synthesized by somatotrophs in anterior 
pituitary, except for during gestation when the placental GH variant pre-
dominates. The synthesis is controlled by several different stimuli, most 
importantly by the hypothalamic hormones GH releasing hormone 
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(GHRH) and somatostatin (SST), both signalling via G-protein coupled 
receptors (GPCRs). Control of GH secretion is subject of chapter 1.1.5. For 
long it was thought that somatotrophs are the only site of GH synthesis 
but according to current evidence GH is produced in several tissues, 
where it acts in an autocrine and paracrine manner [Gahete, 2009; Harvey, 
1997]. Pituitary-specific transcription factor-1 (Pit-1) plays an important 
role in GH synthesis and in somatotroph differentiation. Its expression 
was also thought to be restricted to pituitary but, similarly as in case of 
GH, extrapituitary sites of expression, such as the mammary gland, are 
being identified [Gil-Puig, 2005]. 
The GH-1 gene is preceded by a 26 amino acid signal sequence, which is 
typical for a secreted hormone [Strobl, 1994]. Translation of the mRNA 
transcript takes place on the rough endoplasmic reticulum (RER) whereby 
the preprotein is translocated into the RER lumen. The signal sequence is 
removed by a signal peptidase, the protein is folded and disulfide bridges 
are formed. The mature proteins migrate further to the Golgi apparatus, 
where they are packaged into secretory vesicles [Strobl, 1994; Voet, 2004]. 
The vesicles are released upon increased intracellular cyclic AMP (cAMP) 
and/or free Ca2+. GHRH receptor is coupled to a Gαs and SST receptor to a 
Gαi subunit, ligand binding leading to activation or inhibition of adenylate 
cyclase, respectively [Strobl, 1994]. 
1.1.4.1 GH variants 
In addition to the two genetic variants of GH, i.e. GH-N and GH-V, there 
are many other sources of variation. GH-1 can go through alternative splic-
ing and mature GH can be modified posttranslationally. The GH-1 gene 
consists of five exons (E1-5), four introns (A-D) and untranslated regions 
(UTRs) in 5’ and 3’ termini, as seen in figure 4. Two splice variants, namely 
22 and 20 kD GH, can be synthesised by alternative splicing of intron B/E3. 
After removal of the 26 amino acid signal sequence, 22 kD GH contains 
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191 and 20 kD variant 176 amino acids. Amino acids 32-46 lacking in 20 kD 
GH are located at the end of helix I and in the connecting loop between 
helices I and II. 20 kD GH comprises 5-10% of the GH produced in pitui-
tary but ~15% of the GH in circulation because it has a higher stability 
than 22 kD GH [Baumann, 1999; Kopchick, 2007; Lewis, 1980 & 2000; 
Zhan, 2005].  
 
Figure 4: Alternative splicing of GH-1. All five exons (E1-5) of the GH-1 gene are included in both 
splice variants, but their difference comes from alternative splicing within E3. UTR indicates an 
untranslated region. After removal of signal peptide, the 22 kD variant (isoform 1) contains 191 
and the 20 kD variant (isoform 2) 176 amino acids. Several different posttranslational modifica-
tions are possible, phoshporylation (P) is presented as an example. The figure has been originally 
published by Kopchick [2007]. 
Splice variants must not be confused with circulating GH fragments that 
are result of GH proteolysis. These fragments are to some extent immuno-
reactive but their physiological roles are still under investigation. Some 
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fragments appear to have insulin-like but no growth-promoting activity 
[Baumann, 1999; De Palo, 2006(x2); Lewis, 2000]. 
1.1.4.1.1 Posttranslationally modified variants 
Mature GH can undergo a number of posttranslational modifications. Pla-
cental GH is subject to N-linked glycosylation [Frankenne, 1990; Baumann, 
1999] whereas pituitary GH can be O-glycosylated [Haro, 1996; Busta-
mante, 2009]. These glycosylations result in 25 and 24 kD proteins, respec-
tively. Smaller modifications include phosphorylation, deamidation and 
acylation [Baumann, 1999]. 
1.1.4.1.2 Oligomeric variants 
GH interacts with itself to form dimers and larger oligomers, for the most 
part non-covalently. Also covalent dimers and oligomers occur, most of 
them formed by interchain disulfide bonding [Baumann, 1999; Lewis, 
1977]. GH homodimers are biologically active but to a lower extent than 
monomeric GH [Yang, 2008].  
1.1.4.1.3 GH-GHBP complex 
GH forms a complex with the GH binding protein (GHBP), which equals 
the extracellular domain of GH receptor (GHR). Approximately 50% of 22 
kD GH in circulation is bound to GHBP, predominantly as a 1:1 complex. 
20 kD GH has a somewhat lower binding affinity to GHBP but still 25-30% 
of it is GHBP-bound. GHBP protects GH from degradation and physio-
logical clearance but at the same time keeps it unavailable for GHR 
[Baumann, 1988 & 1994]. 
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1.1.5 From hypothalamus to periphery and vice versa 
Hypothalamus is the master organ that plays the most essential role in 
controlling GH secretion. GHRH stimulates and SST inhibits GH release. 
There are however numerous other factors that are involved in the control 
of GH secretion. As summarized in figure 5, the other major regulators are 
ghrelin, leptin and free fatty acids (FFAs), GH itself and its second mes-
senger insulin-like growth factor-1 (IGF-1). Additional hormonal and 
metabolic regulators include e.g. sex steroids, glucocorticoids and amino 
acids, which are not discussed here in further detail [Chowen, 2004; 
Müller, 1999]. GH secretion can be controlled either by influencing GHRH 
and SST release from hypothalamus, by interacting directly with the ante-
rior pituitary, or by both mechanisms.  
 
Figure 5: Control of GH secretion. GH release from anterior pituitary depends on a large amount 
of signals. Some of the signals act through hypothalamus. 
1.1.5.1 Hypothalamic control of GH secretion 
The hypothalamic hormones GHRH and SST regulate both GH-1 gene 
transcription and GH release from the somatotrophs. Transcription control 
is mediated by various transcription factors, particularly Pit-1 [Müller, 
1999; Pombo, 2001]. GHRH is mainly expressed in the arcuate nucleus and 
SST in the periventricular nucleus of hypothalamus [Fodor, 2006, Lopéz, 
2010]. Their secretion is regulated hormonally and metabolically, most im-
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portantly by GH feedback [Müller, 1999]. Hypothalamic interactions play 
an important role as well: orexinergic neurons mediate information about 
sleep-wake cycle and energy homeostasis [Lopéz, 2010]. 
1.1.5.2 Ghrelin 
Ghrelin is a gastric peptide best known for its GH-releasing and orexigenic 
effects even though it has numerous other actions both on hypothalamus-
pituitary level and in periphery. Ghrelin is secreted upon energy restric-
tion and needs to be acetylated in order to bind to the growth hormone 
secretagogue receptor type 1a (GHS-R1a) [Ghigo, 2005; van der Lely, 2004]. 
GHS-R1a is very prominent in hypothalamus and pituitary and it is be-
lieved that ghrelin has its GH-releasing effect both by regulating hypotha-
lamic GHRH and SST and by directly stimulating GH secretion from the 
pituitary. At the pituitary level ghrelin acts as a SST antagonist and also 
has a direct impact on GH-release but still its action on the hypothalamic 
level is believed to have a greater significance [Kineman, 2007; Maghnie, 
2007; Tannenbaum, 2003; van der Lely, 2004]. The detailed interaction be-
tween ghrelin, GHRH and SST remains to be solved. 
1.1.5.3 Adipose tissue 
In opposite to ghrelin, leptin is a hormone that is secreted upon satiety. It 
is secreted from white adipose tissue as a response to sufficient energy 
stores and, as a result, circulating leptin levels correlate with body fat 
mass. Leptin signals via its receptor isoform b, ObRb, which is very 
prominent in hypothalamus, the main site of leptin action [Boguzewski, 
2010; Kelesidis, 2010]. Leptin has been shown to be able to modulate GH 
secretion but its role is still somewhat unclear: fasting and thereby de-
creased leptin levels lead to increased GH levels in humans but decreased 
GH levels in rats. Obesity on the other hand results in impaired growth 
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hormone axis, whereby it is difficult to distinguish the effect of leptin [Ga-
hete, 2009; Müller, 1999; Pombo, 2001].  
Free fatty acids that are released from the adipose tissue after lipolysis in-
hibit GH secretion. They have been suggested to act directly on pituitary, 
inhibiting the action of GHRH [Alvarez, 1991; Pombo, 2001]. 
1.1.5.4 Feedback inhibition 
GHRH, SST, GH itself and its ubiquitous second messenger IGF-1 form a 
complex feedback regulation of GH production, including long, short and 
ultrashort feedback loops [Gahete, 2009; Giustina, 1998; Müller, 1999]. GH 
regulates its own production in an autocrine/paracrine manner at the pi-
tuitary level but also via a long feedback loop [Gahete, 2009]. Mechanism 
of the autofeedback action of GH is not completely clear but GH is known 
to stimulate SST and inhibit GHRH, thus inhibiting its own production 
[Asa, 2000; Giustina, 1998; Müller, 1999]. IGF-1 acts along GH in the long 
feedback loop by stimulating SST release from hypothalamus and directly 
inhibiting GH release on pituitary level [Gahete, 2009; Müller 1999]. Both 
GH and IGF-1 can to some extent cross the blood-brain barrier, enabling 
their direct interaction with the hypothalamus [Pan, 2005; Reinhardt, 
1994].  
1.1.5.5 GH action 
A simplified version of GH action is presented in figure 6. Once GH enters 
the circulation it is transported to target organs, partly bound to GHBP 
[Baumann, 1990]. GHR mRNA is expressed in various human tissues, 
above all in liver, adipose tissue, muscle and kidney, indicating high GH 
activity in these tissues [Ballesteros, 2000; Kaplan, 2007]. GH is best known 
for its growth promoting effects but it has also a number of metabolic ac-
tions. 
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Figure 6: GH-axis. GH release from anterior pituitary is regulated among others by GHRH, SST 
and ghrelin. In circulation approximately 50% of GH is bound to GHBP. In the target organs GH 
has metabolic actions and growth-promoting effects, which are mediated by IGF-1. Liver is an 
important site of IGF-1 production but it is also produced locally at target tissues.  
1.1.5.5.1 Growth 
GH markedly promotes skeletal muscle growth and longitudinal bone 
growth and remodelling [LeRoith, 2001]. These effects are mediated by 
IGF-1, also known as somatomedin. According to the original somatomedin 
hypothesis, GH-induced IGF-1 secretion from the liver was responsible for 
the growth-promoting effects of GH. In the updated hypothesis an impor-
tant role is given to local IGF-1 production upon GH stimulation and its 
autocrine/paracrine action. In addition GH stimulates synthesis of IGF 
binding protein-3 (IGFBP-3) and acid-labile subunit (ALS), which are im-
portant IGF-1 carriers in circulation [Kaplan, 2007; LeRoith, 2001; 
Rosenfeld, 2009; Yakar, 1999]. 
1.1.5.5.2 Metabolism 
The various metabolic actions of GH are summarized in table 2. Some but 
not all of them are mediated by IGF-1 but for most part the effects are in-
separable [Mauras, 2005]. It is undisputed however that GH has a direct 
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anti-insulin effect on carbohydrate metabolism whereas IGF-1 has an insu-
lin-like effect [LeRoith, 2007; Mauras, 2005]. GH reduces glucose uptake, 
stimulates gluconeogenesis and increases mobilization of lipids by stimu-
lating lipolysis and β-oxidation and inhibiting lipogenesis. The role GH 
has in protein metabolism is metabolically less significant – the promotion 
of protein synthesis in muscle can be considered as a growth promoting 
effect [LeRoith, 2001 & 2007; Mauras, 2005; Møller, 2009] 
Table 2: Metabolic actions of GH. It is not specified which effects are IGF-
1-mediated. However, the effect on glucose metabolism is by GH alone 
[LeRoith, 2001 & 2007; Møller, 2009]. 
 + - 
Carbohydrates gluconeogenesis glucose uptake 
Proteins protein synthesis  
Lipids 
lipolysis 
β-oxidation 
ketogenesis 
lipogenesis 
 
1.1.5.5.3 Immunology 
Lymphocytes are both a target and a production site of GH. GH stimulates 
thymopoiesis, proliferation of T and B cells and production of cytokines. 
Furthermore it increases macrophage and neutrophil activity and inhibits 
apoptosis [Hattori, 2009; LeRoith, 2001]. The immunomodulatory effects of 
GH are at least to some extent mediated by IGF-1 [Dorshkind, 2000; Hat-
tori, 2009].  
1.1.5.5.4 Renal function 
GH, via IGF-1, reduces renal vascular resistance and increases renal 
plasma flow and glomerular filtration rate, leading to hyperfiltration. GH 
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also increases renal sodium and fluid retention, which could lead to hy-
pertension at elevated GH levels [Ogle, 1992(x2)]. 
1.1.6 GH signalling 
1.1.6.1 Growth hormone receptor 
Most actions of GH are launched by GH binding to the GH receptor, GHR. 
Full-length GHR has 620 amino acids. N-terminal residues 1-246 form the 
extracellular domain (ECD), which equals GHBP. C-terminal residues 271-
620 form the intracellular domain (ICD), and the amino acid portion in 
between consists of hydrophobic amino acids which reside in the trans-
membrane region [Godowski, 1989; Leung, 1987]. 3D structure of the ICD 
is not known whereas the ECD is made up of two fibronectin type III do-
mains, as can be seen in figure 7 [de Vos, 1992; Brooks, 2007]. Human 
GHBP is generated by proteolytic cleavage from the GHR but in rodents it 
is a splice variant of GHR [Baumann, 1994]. 
There are three known GHR isoforms besides the full length GHR: GHR1-
277, GHR1-279 and GHR-d3, in which exon 3 (out of 1-10) is skipped, re-
sulting in loss of amino acids 7-38. Biological properties of GHR-d3 do not 
differ from the full-length GHR [Seidel, 2003]. Since GHR1-277 and GHR1-
279 lack most of the ICD, they cannot initiate signal transduction. GHR1-
279 is more common (<10% of total GHR in liver, fat and muscle) than 
GHR1-277 (<1%) but both seem to have a very similar biological signifi-
cance: they are dominant-negative inhibitors of the full-length receptor 
and shed large amounts of GHBP [Ballesteros, 2000; Ilda, 1999; Ross, 1997]. 
GHR is a class I cytokine receptor, and thus has no intrinsic kinase activity 
and requires associated kinases for tyrosine phosphorylation [Wells, 1996]. 
Tyrosine phosphorylation is the first step in signal transduction, which is 
the subject of chapter 1.1.6.2. For a long time it was believed that ligand 
binding causes the receptor to dimerize but it turned out that the receptor 
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is present on cell surface as a constitutive dimer [Gent, 2002] and ligand 
binding induces a conformational change which triggers intracellular 
kinase activation [Brooks, 2007; Brown, 2005]. Upon GH binding a disul-
fide bond is formed between C241 residues of the GHR ECDs but this 
linkage is not necessary for initiation of the intracellular signal transduc-
tion [Brown, 2005; Zhang, 1999]. GH binding to a pre-existing GHR dimer 
and the consequential conformational change are depicted in figure 7.  
 
Figure 7: GHR activation. GHR is found on the cell surface as a pre-existing dimer. GH binding 
results in a conformational change that triggers intracellular signalling. The blue ellipses are inacti-
vated Jak2s (Janus kinase 2, see chapter 1.1.6.2), which become activated (red spheres) upon 
ligand binding. The red line represents a disulfide bond, which is formed at receptor C241 as a 
result of the conformational change [Brown, 2005]. 
1.1.6.1.1 GH binding site 1 and 2 
GH has two GHR binding sites, which bind to roughly the same site on the 
receptor [Cunningham, 1991; Wells, 1996]. The relevant amino acids for 
each binding site on GH as determined by Cunningham are indicated on 
figure 8. Binding site 1 has very high affinity to GHR whereas the affinity 
of binding site 2 is much lower. In alanine mutation studies 22 amino acids 
were reported to be critical for site 1 binding but only five for site 2 bind-
ing. Helix II does not contain such amino acids, helix I contains amino ac-
ids that are essential for both binding sites, helix III is important for bind-
ing site 2 and helix IV for binding site 1 [Cunningham, 1991]. 
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Figure 8: GHR binding sites of GH. GHR binding site 1 is sea green and 2 blue on the pink GH 
molecule, which is here in the same position as the model by Cunningham [1991] containing the 
amino acids that are important for binding at each site. Helix II doesn’t include critical amino 
acids, helix I contains amino acids that are essential for both binding sites, helix III is important for 
binding site 2 and helix IV for binding site 1. Molecular modelling of PDB entry 1HGU [Chantalat, 
1995] was done with RasMol. 
GH binds to GHR sequentially: site 2 binding does not occur until binding 
site 1 is associated with receptor [Cunningham, 1991; de Vos, 1992]. This is 
due to an allosteric change caused by site 1 binding [Walsh, 2004].  
1.1.6.2 Signal transduction 
Janus kinases (Jaks) are a family of receptor kinases that mediate signal-
ling of cytokine receptors. The family consists of Jak1, 2 and 3 and tyrosine 
kinase 2 (Tyk2), of which Jak2 interacts with GHR [Rosenfeld, 2009; Wells, 
1996]. Each GHR ICD can be associated with one Jak2, which is activated 
upon ligand binding. The conformational change brings the two ICDs and 
thereby the Jak2s closer together, which allows the Jak2 on one GHR ICD 
to transphosphorylate the Jak2 on the other. Consequently several tyrosine 
residues on the GHR are phosphorylated, launching signal transduction 
pathways [Brown, 2005; Lanning, 2006; Waters, 2006]. 
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1.1.6.2.1 Jak/STAT pathway 
The so called Jak/STAT pathway (see figure 9) is the major signal transduc-
tion pathway in GH signalling. The role of Jak (Jak2) was already pre-
sented above. STATs are a family of “signal transducers and activators of 
transcription”, consisting of STATs 1, 2, 3, 4, 5a, 5b and 6. STAT1 and 
STAT3 can to some extent be activated by GHR but STAT5a and STAT5b 
are the most critical STATs for GH signalling [Paukku, 2004; Rosenfeld, 
2009; Wells, 1996].  
 
Figure 9: Jak/STAT signalling pathway. Jak2 bound to GHR is activated upon ligand binding, which 
leads to phosphorylation of Jak2 on the adjacent GHR. Consequently also the GHR and STAT 
bound to it are phosphorylated. Phosphorylated STAT5 homo/heterodimerizes and translocates 
into the nucleus, where it activates the transcription of target genes.  
STATs bind to the activated GHR-Jak2 complex, where they as well are 
phosphorylated and thereby activated. Activated STATs form homo- or 
heterodimers, which are translocated into the nucleus, where they func-
tion as transcription factors [Lanning, 2006; Rosenfeld, 2009]. The activated 
genes include e.g. IGF-1 [Cesena, 2007; Woelfle, 2003] and certain members 
of a family of suppressors of cytokine signalling (SOCS). SOCS can either 
bind to Jak2 or GHR, hampering the activating phosphorylations, or block 
STAT5 binding sites on GHR [Croker, 2008; Lanning, 2006].  
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1.1.6.2.2 Additional pathways  
Activation of Jak2 can initiate at least two other pathways in addition to 
the Jak/STAT pathway, namely the phosphatidylinositol 3-kinase (PI3K) 
and mitogen-activated protein kinase (MAPK) pathways. Signalling may 
also take place Jak2-independently via Src tyrosine kinases which also 
leads to activation of the MAPK pathway. Also these pathways lead to ac-
tivation of target genes [Brooks, 2007; Lanning, 2006]. However, these ad-
ditional pathways are not enough to maintain the necessary GH-induced 
IGF-1 levels in absence of STAT5 [Rosenfeld, 2009].   
1.1.6.3 Recycling of GHR 
Half-life of GHR is approximately 1 h [Brooks, 2007]. GHR is recycled by 
ubiquitin-dependent internalization and lysosomal degradation of the 
GHR-GH-GHR complex [Frank, 2008; van Kerkhof, 2007]. GHR1-279 is 
internalized at a much lower rate than full-length GHR, which accounts 
for its dominant negative action [Maamra, 1999]. Another means for recy-
cling is the proteolytic shedding of GHBP followed by release of the ICD 
into the cytosol [Frank, 2008]. The ICD remnant has been suggested to 
have GH-independent roles e.g. in regulation of gene transcription 
[Cowan, 2005]. 
1.1.7 GH in health and disease 
1.1.7.1 Normal GH levels 
GH is secreted in a pulsatile manner and is stimulated above all by sleep 
and exercise [Müller, 1999; Strobl, 1994]. GH levels are highest during pu-
berty [Strobl, 1994] and then during adult life decrease 14% per decade 
[Toogood, 1996]. Changes in GH secretion do not affect the intervals be-
tween pulses but rather their amplitude [Müller, 1999; Strobl, 1994]. GH is 
secreted on average 12 times a day and since its half-life is only 15-18 min-
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utes, the basal GH levels are very low. Mean (24h average) serum GH con-
centration is 0.8 µg/l in women and 0.3 µg/l in men and peak values are 2.1 
µg/l and 0.7 µg/l, respectively [van den Berg, 1996].  
1.1.7.1.1 The sex factor 
GH levels are 2-3-fold higher in women than in men. Women have a 
higher maximal GH plasma concentration and their GH pulses are pro-
longed while the frequency remains the same as in men [van den Berg, 
1996]. Also exercise-induced GH secretion is more notable in women than 
in men [Strobl, 1994]. These differences are at least partly mediated by oes-
trogen [Chowen, 2004; Leung, 2004; Strobl, 1994]. 24-h curves of female vs. 
male GH plasma concentrations are shown in figure 10. Secretion rates 
were calculated based on the plasma concentrations by “multiparameter 
deconvolution analysis” [van den Berg, 1996].  
 
Figure 10: 24-h plasma GH levels. Samples were collected at 10-min intervals and their concen-
trations were measured by a highly sensitive immunofluorometric assay. GH secretion rate was 
calculated from plasma GH concentration by multiparameter deconvolution analysis [van den 
Berg, 1996]. 
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1.1.7.1.2 Gestation 
Pituitary GH concentration is reported to decrease during gestation, being 
partially replaced by placental GH. Overall GH level is rather low during 
the transition period, contributing to storage of fat [Freemark, 2006].  
GH seems to be rather unimportant for prenatal growth – unlike IGF-1. 
This can be observed in birth weights of neonates with either GH/GHR or 
IGF-1/IGF-1 receptor deficiencies: only the latter have retarded intrauter-
ine growth whereas postnatal growth will be impaired in both cases 
[Rosenfeld, 2009]. 
1.1.7.2 Excess GH 
Acromegaly is a rare condition, where elevated GH levels cause over-
growth of extremities and soft tissue hypertrophy. Typical facial features 
of acromegalic patients can be seen in figure 11. Symptoms and conse-
quences include e.g. sweating, joint pain, sleep apnoea, hypertension and 
diabetes. Basal (between peaks) plasma GH concentration in acromegalic 
patients is above 0.4 µg/l (see figure 10) [Chanson, 2008]. Childhood GH 
excess is called gigantism: as long as the epiphyseal growth plates are 
open, high GH levels result in excessive linear growth [Eugster, 1999]. 
Somatotroph pituitary adenomas are the most common cause in both ac-
romegaly and gigantism. Extrapituitary causes include impaired GHRH or 
SST secretion [Chanson, 2008; Eugster, 1999]. These conditions are primar-
ily treated by surgery but if it cannot be accomplished or does not normal-
ise GH levels, radiotherapy and/or medical treatment is applied. The latter 
includes SST analogues and dopamine agonists, dopamine being one of 
the hypothalamic mediators of SST release [Bush, 2008; Chanson, 2008; 
Müller, 1999]. A rather new approach is the use of a GHR antagonist, Peg-
visomant. 
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Figure 11: Typical features of acromegalic patients. Bulge in the forehead, big nose, prominent jaw 
and thick lips and tongue are common outer signs of excess GH [Chanson, 2008]. 
1.1.7.2.1 Pegvisomant 
Pegvisomant is an analogue of human GH but the mutation G120K makes 
it a GHR antagonist. The antagonist effect of such a mutation was discov-
ered in 1990 [Chen, 1990]. G120 is located in proximity of GH binding site 
2 and replacing the tiny glycine with a bulkier amino acid prevents correct 
GHR binding on this binding site. The original findings were based on a 
G120R mutation but the mutation currently in use is G120K. Since the 
G120K mutant cannot initiate the intracellular conformational change re-
quired for signal transduction but still occupies the receptor via high-
affinity binding on binding site 1, it acts as a GHR antagonist. The antago-
nistic effect and medical applicability of the molecule have been improved 
by adding eight additional mutations that enhance site 1 binding and 4-6 
polyethylene glycol (PEG) residues to increase the half-life [Kopchick, 
2002]. On the other hand, the PEG residues cause a 30-40-fold reduction in 
binding affinity to GHR but this does not outweigh the benefits [Prad-
hananga, 2002; Ross, 2001]. Pegvisomant treatment of acromegaly has 
proven very efficient: 90% of subjects reach normal IGF-1 levels. The high 
dose up to 40 mg/day was an initial concern but no severe side effects have 
been reported so far [Higham, 2008; Kopchick, 2002]. 
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1.1.7.2.2 GH abuse in sport 
Because of its protein anabolic effects, GH is of interest for athletes and 
bodybuilders. Recombinant human 22 kD GH (rhGH) is being used as a 
doping agent even though its efficacy has not been proven and it may lead 
to a condition similar to acromegaly [Saugy, 2006]. Detection of GH abuse 
is complicated because rhGH does not differ from the endogenous hor-
mone and its half-life is rather short. However, upon exogenous GH ad-
ministration, the normal mixture of GH variants is impaired and the usage 
of rhGH can be detected using high-sensitivity immunoassays that meas-
ure the proportions of GH isoforms, especially 20 vs. 22 kD GH [Bidling-
maier, 2009]. 
1.1.7.3 GH deficiency and Kowarski syndrome 
There are four types of familial isolated GH deficiency (IGHD), caused by 
a variety of genetic disorders resulting in impaired GH secretion. The 
classes of IGHD, their inheritance and cause are summarized in table 3. 
Diagnosis of childhood IGHD is complex but a height more than 3 SD be-
low mean and a peak GH value <10 µg/l after provocation test are typical 
criteria [GH Research Society, 2000]. 
Table 3: Classification of GH deficiency. 
IGHD type Inheritance [GH] Candidate gene 
IA recessive absent GH-1 
IB recessive low GH-1, GHRH, GHRHR etc. 
II dominant low GH-1 
III X-linked low unknown 
In IGHD type IA the GH-1 gene is deleted or silent due to frameshift or 
nonsense mutations. This condition is recessively inherited and leads to 
severe dwarfism by the age of six months [Mullis, 2007]. As can be con-
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cluded by the recessive inheritance, one functional GH-1 gene suffices for 
normal growth [Binder, 2002]. Since GH is completely absent in IGHD 
type IA patients, treatment with rhGH is problematic due to generation of 
anti-GH antibodies [Mullis, 2007]. IGHD type IB is also recessively inher-
ited but less severe than type IA due to detectable GH levels. In addition 
to GH-1, also genes encoding GHRH, its receptor (GHRHR) or regulators 
of GH-1 gene transcription may be altered [Mullis, 2007].  
IGHD type II differs from type I particularly by its dominant inheritance. 
Most common cause is any of several mutations of the GH-1 gene, which 
cause skipping of exon 3 (Δexon3), i.e. amino acids 37-71, and result in a 
17.5 kD GH. This variant has a dominant negative effect by interfering 
with 22 kD GH secretion [Mullis, 2007]. Also missense mutations of GH-1 
have been reported to cause IGHD type II, for instance P89L, V110L and 
R183H, which all substitute extremely conserved amino acids (see table 1) 
[Binder, 2001; Mullis, 2007; Salemi, 2005]. Their positions on a GHBP-GH-
GHBP complex can be seen in figure 12. 
IGHD type III is the rarest kind of IGHD and has an X-linked recessive 
inheritance. It is caused by alterations in the X chromosome, which proba-
bly are related to genes involved in immunoglobulin production since 
these patients are also missing immunoglobulins [Mullis, 2007]. 
Kowarski syndrome is caused by bio-inactive GH. It differs from IGHD by 
normal to high GH levels and from Laron syndrome by functional GHR 
[Kowarski, 1978].  In Laron syndrome growth retardation is due to defects 
on GHR level [Laron, 1966]. Three GH-1 mutations have been reported to 
cause Kowarski syndrome, a homozygous C53S mutation [Besson, 2005] 
and heterozygous R77C and D112G mutations [Chihara, 1998; Takahashi, 
1996 & 1997]. Heterozygous I179M [Lewis, 2004] and D116E [Dateki, 2009] 
mutations have also been identified in patients with short stature but no 
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evidence for bio-inactivity was found. Positions of these missense muta-
tions on a GHBP-GH-GHBP complex are indicated in figure 12. 
 
Figure 12: GH-1 missense mutations associated with short stature. A pink GH molecule is bound to 
two GHBPs, light yellow on binding site 2 and light sea green on binding site 1. Amino acids which 
undergo substitution mutations in patients with short stature are indicated. The corresponding 
mutations are C53S, R77C, P89L, V110L, D112G, D116E, I179M and R183H. RasMol was used for 
molecular modelling. PDB ID of the 3D model is 1HWG [Sundström, 1996]. 
1.1.7.3.1 A novel GH-1 deletion mutation leading to short stature 
Some years ago a novel GH-1 mutation was identified in twin girls, who 
were born in 1990, and in their mother and her father. They were first di-
agnosed with GH deficiency based on heights between -3.76 and -2.69 SD 
and peak GH concentrations between 6.6 and 7.3 µg/l [Weigel, 2004]. Their 
GH-1 was sequenced and a heterozygous deletion of nine base pairs was 
revealed, resulting in deletion of three amino acids at C-terminus, Δ188-
190. Unfortunately the girls did not respond very well to rhGH therapy 
but still final heights of 148 and 150 cm were achieved [unpublished data]. 
It was thought that the phenotype was similar to that of Δexon3 patients 
[Weigel, 2004] until it turned out that the GH concentrations had actually 
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been unusually high but could not have been detected in a conventional 
GH assay. Measurements done in our group using highly sensitive fluo-
rescent immunoassays revealed GH levels up to 50 µg/l. The reason why 
the patients’ GH could not have been detected in the conventional assay 
was that approximately 80% of it was in dimeric form, as shown by West-
ern blot, fast protein liquid chromatography (FPLC) and immunoassays 
employing monoclonal antibodies that are able to distinguish between GH 
monomer and dimer.  
Since many of the mutations associated with short stature involve the dis-
ulfide bridges of GH, a closer look is taken into the contribution of disul-
fide bridges for protein – and especially GH – structure in chapter 1.2. 
1.2  Disulfide bridges 
1.2.1 Formation and contribution to structure 
The amino acid cysteine has the unique ability to form disulfide bonds to 
other cysteine residues through oxidation of their thiol groups:  
R-SH + HS-R  R-S-S-R + 2H+ + 2 e- 
The reaction occurs spontaneously in an oxidising environment but can 
also be assisted by protein disulfide isomerases (PDIs), which catalyse di-
sulfide interchange reactions. Disulfide bridge formation during protein 
synthesis takes place in the oxidising environment of ER [Voet, 2004]. Di-
sulfide bonds are not needed for correct folding of proteins but rather sta-
bilize the correct 3D structure [Betz, 1993; Voet, 2004]. 
1.2.2 Disulfide bridges in GH 
As already mentioned in chapter 1.1.3, the GH family members have a 
four helix bundle structure with an up-up-down-down motif. Pituitary 
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and placental hGH, hPL, hPRL and bGH, which were aligned in table 1, all 
have a disulfide bridge linking the crossover connection between helices I 
and II to helix IV. They all also have a C-terminal small loop and hPRL has 
an additional small loop at N-terminus [Chantalat, 1995; Teilum, 2005; 
Walsh, 2006]. The disulfide bridges are conserved not only throughout 
these family members but also more extensively throughout species [Wa-
tahiki, 1989; Nicoll, 1986].  
The disulfide bridge between C53 and C165 has shown to be essential for 
both GH secretion and function [Besson, 2005; Chen, 1992; Gráf, 1976; Iliev, 
2005]. The C-terminal disulfide bridge between C182 and C189 has been 
reported to be unimportant for biological potency, secretion and receptor 
binding but has not been under as much investigation as the other disul-
fide bridge [Chen, 1992; Gráf, 1976]. The conservation still speaks for its 
importance. 
Several of the mutations that are associated with short stature somehow 
interfere with the disulfide bridges of GH. C165 is deleted as a conse-
quence of Δexon3 mutations causing IGHD type II [Mullis, 2007] and its 
counterpart, C53, is mutated in the case of Kowarski syndrome caused by 
a homozygous C53S mutation [Besson, 2005]. R183H mutation that is also 
associated with IGHD type II is adjacent to the C182 of the C-terminal di-
sulfide bridge and may interfere with its formation [Binder, 2001]. In addi-
tion, a C182R mutation has been identified in a hypertension patient but 
the mutant did not differ from wild type (wt) GH in in vitro experiments 
and causality could not be shown [Horan, 2006]. Finally, the C-terminal 
disulfide bridge is disrupted in the novel heterozygous mutation Δ188-190 
due to deletion of C189. These mutations being able to cause short stature 
indicate an important role for the disulfide bridges – also for the one in C-
terminus.  
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2 Aim 
The primary aim of this PhD project was to characterize the novel GH de-
letion mutant Δ188-190 and to reveal its mechanism of causing short stat-
ure. The possible antagonistic effect of Δ188-190 on GHR was especially 
under focus. Firstly the mutant had to be produced in vitro and secondly 
suitable methods for its characterization had to be established. Important 
aspects for characterization of GH variants and mutants are expression 
and secretion, binding affinity to GHR and to GHBP, biological activity 
and stability. Since the novel mutation disrupted the C-terminal disulfide 
bridge of GH and since the role of this extremely conserved structural fea-
ture was rather unknown, we decided to take a closer look into its contri-
bution to the molecule as well. This was done by substituting the involved 
cysteines with alanines. GH mutants that had been reported to be associ-
ated with short stature were another matter of interest. We chose to inves-
tigate R77C because it had been suggested to be a GHR antagonist al-
though this hypothesis has meanwhile been proven wrong. We were 
curious about D112G since it had only been characterized as it was first 
reported in 1998 and was claimed to be biologically inactive. We therefore 
investigated the properties of the new mutant Δ188-190 in comparison to 
previously published GH mutants and newly designed GH mutants with 
a modified C-terminus. 
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3 Materials and methods 
Suppliers of the chemicals and reagents, laboratory equipment, kits, con-
sumables and software used in this project can be found in appendix III.  
3.1 Recombinant DNA work 
First practical step of this project was to construct expression plasmids 
containing either mutated or wt human GH-1 gene. Compositions of 
working solutions needed for the recombinant DNA work are listed in 
table 4.  
Table 4: Compositions of the working solutions in chapter 3.1 (*was prepared sterile). 
Agarose  gel, 1%  1% agarose (w/v) in 1x TBE, dissolved by boiling  
 1:10,000 CYBR® Safe DNA gel stain added once cooled down 
TBE, 10x  0.89 M Trizma® base, 0.89 M boric acid and 20 mM EDTA in 
ddH2O 
 autoclaved 
Loading dye, 6x  0.25% bromophenol blue (w/v) and 30% glycerol in TE buffer 
  short-term storage at 4°C, long-term in -20°C 
TE buffer  10 mM Trizma® base and 1 mM EDTA in ddH2O 
 pH 8.0 (HCl) 
 autoclaved 
Lysogeny 
broth/ampicillin 
(LB/amp) medium 
 1 LB Broth tablet per 50 ml ddH2O 
 autoclaved 
 stored at 4°C 
 100 µg/ml ampicillin added before use 
Ampicillin, 10 
mg/ml* 
 20 mg ampicillin in 20 ml sterile ddH2O 
 filtrated with a 0.2 µm filter 
 stored in -20°C 
LB/amp plates*  1 LB Agar tablet per 50 ml ddH2O  
 autoclaved  
 100 µg/ml ampicillin added once cooled down to ca 55°C 
 ca 20 ml poured per Petri dish 
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3.1.1 Site-directed mutagenesis 
Plasmid pGH-Sec-Tag-GH-stop containing the human GH-1 gene pre-
ceded by 26 aa signal sequence [Strobl, 1994] was a kind gift from Dr. Ian 
Wilkinson (Sheffield, UK). Sequence of GH-1 and signal sequence can be 
found in appendix V. The GH-1 gene was amplified and mutated by PCR. 
The GH forward primer included a 5’ CACC, which functions as a recog-
nition sequence in directional TOPO cloning, which is described in chapter 
3.2.2.  
Mutations C182A, C189A and Δ188-190 were introduced by using a re-
verse primer containing the mutation in question. In case of R77C and 
D112G, the mutagenesis had to be performed in two steps. First the muta-
tion was introduced in two overlapping segments using GH forward and 
mutated reverse primer for one segment (IA in figure 13), and mutated 
forward and GH reverse primer for the other (IB in figure 13). Then these 
two segments were used as template in a subsequent PCR employing GH 
forward and reverse primers (II in figure 13).  
 
Figure 13: Two-step PCR. The DNA strands represent double-stranded template and PCR-
product and not the actual steps of PCR. Fwd refers to forward and rev to reverse primer, and 
mut to mutant. 
Mutation C182+9A was introduced by using the C182A mutated GH-1 
gene as template and the reverse primer containing the C189A mutation. 
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All primers are listed in appendix IV. Mutagenesis and cloning of the 
D112G mutant were performed by Friederike Braig during her Bachelor’s 
thesis project. C182A and C189A were generated by Adna Halilovic and 
Heike Wobst during their Molecular Medicine Module II practical train-
ing. Ingredients of each PCR reaction and the used program are listed be-
low. Template was either 10 ng plasmid pGH-Sec-Tag-GH-stop or 5 ng of 
both first round PCR products. Concentration of dNTP mix refers to the 
final concentration of each nucleotide. Pfu DNA polymerase, which has 
proof-reading ability, was used because blunt-ends were required for con-
struction of the expression vector (see chapter 3.1.2). PCR was run on a 
Mastercycler Personal. 
PCR composition Program 
10 ng template 
200 nM fwd & rev primers 
200 µM dNTP mix 
1x Pfu reaction buffer 
0.6 units Pfu DNA polymerase 
ddH2O up to 50 µl 
2’ 94°C 
30’’ 94°C 
30’’ 58°C          30x 
2’ 72°C 
10’ 72°C 
Correct size of PCR products was verified on 1% agarose gel, based on 100 
bp DNA Ladder. Ladders and samples were always mixed 5:1 with load-
ing dye before loading on gel and all gels were scanned with Typhoon 
8600 Variable Mode Imager. The bands of proper size were excised from 
gel and purified using QIAquick Gel Extraction Kit, after which some of 
the purified product was run on 1% agarose gel together with Low DNA 
Mass™ Ladder so that their concentrations could be estimated. This was 
necessary for the second PCR step of R77C and D112G and for cloning of 
all final PCR products, which is the subject of the subsequent chapter.  
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3.1.2 Construction of pcDNA3.1-GH 
Purified PCR product was subcloned into the expression vector pcDNA3.1 
V5-His-TOPO – briefly pcDNA3.1 – using pcDNA™3.1 Directional TOPO® 
Expression Kit and following its instructions. The principle behind direc-
tional TOPO cloning is the use of topoisomerases and a GTGG recognition 
sequence, which guarantees correct insert orientation. The vector and its 
recognition sequence are shown in figure 14. Positive clones would be 
ampicillin-resistant so the transformed Escherichia coli (E. coli) TOP10 bac-
teria were grown on LB/amp plates o/n at 37°C in an Orbital Shaker Incu-
bator without shaking. On the following day some of the colonies were 
chosen for amplification in 3.8 ml LB/amp medium and cultured as the 
plates but with 150 rpm. 0.8 ml of each culture was used for a glycerol 
stock, hence mixed 4:1 with 80% glycerol and stored in -80°C. Plasmids 
were isolated from the remaining bacteria with QIAprep Spin Miniprep 
kit. 
 
Figure 14: Structure of the directional TOPO cloning vector. The GTGG of the insert is cleaved off 
while the GTGG of the vector (red circle) becomes part of the plasmid. The figure was modified 
from the pcDNA3.1 Directional TOPO® Expression Kit -manual. 
3 Material and methods 
 32 
The obtained plasmids, i.e. the “minipreps”, were digested with BamHI & 
BglII in REact®3 buffer and with HindIII & EcoRV in REact®2 buffer for fur-
ther analysis.  
Restriction analysis composition  
5 µl miniprep 
2 µl 10x REact® buffer 
0.5 µl = 5 units enzyme I 
0.5 µl = 5 units enzyme II 
autoclaved ddH2O up to 20 µl 
 
 1-2 h at 37°C 
+ 4 µl 6x loading dye 
 10 µl on 1% agarose gel 
Restriction maps had been created with Redasoft Visual Cloning software, 
and a simplified version is presented in figure 15. Restriction sites of none 
of the used enzymes were lost by introducing the mutations mentioned in 
chapter 3.1.1 but the deletion mutation Δ188-190 reduced plasmid size and 
EcoRV restriction site by 9 bp. 
 
Figure 15: Restriction map of pCDNA3.1-GH (wt). Restriction sites are based on analysis with 
Redasoft Visual Cloning. By digesting the plasmid with BamHI and BglII, which has one restriction 
site within the insert and another in vector, one can verify the presence and correct orientation 
of insert. EcoRV and HindIII cut on vector on both sides of insert and thus give information about 
insert size.  
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For each mutant and for wt GH, one clone that showed correct structure in 
restriction analysis, based on 100 bp and 1 kb DNA ladders, was chosen 
for large-scale amplification. Firstly LB/amp plates were inoculated with 
the glycerol stocks and incubated o/n at 37°C. In the following morning 2-
3 ml o/d cultures with a single colony from each plate were started and 
these were transferred to 100 ml o/n cultures in the evening. HiSpeed® 
Plasmid MIDI kit was used for plasmid isolation and TE buffer for DNA 
elution. Finally correctness of constructs was verified by sequencing the 
plasmids with the standard primers T7 and BGH-rev at IIT Biotech (Biele-
feld, Germany). With these plasmids one can sequence the error prone 
junctions between insert and vector. Also these primer sequences are listed 
in appendix IV, and in addition their sites are indicated on the vector se-
quence in appendix V. 
3.2 Cell culture 
A few different cell lines were employed during the characterization of the 
mutants. All of them were cultured in 75 cm2 flasks at 37°C in a CO2 incu-
bator, in the presence of 10% CO2. Their culture media are listed in table 5. 
Human embryonic kidney (HEK)-293 cells, received from Heike Bieber-
mann (Berlin, Germany), were used for production of recombinant GH. 
HEK-293 cells stably transfected with hGHR, i.e. HEK-293-GHR cells, were 
a gift from Richard Ross (Sheffield, UK). HEK-293-GHR cells were used 
for STAT5 transcription assay and GHR binding assay. Both HEK-293 and -
GHR cell lines were passaged 1:4-7 every 3-4 days by rinsing with PBS, 
trypsinising and resuspending in fresh culture medium.  
BaF-B03-B2B2 cells, which also are stably transfected with hGHR, had 
been a gift from Mauro Bozzola (Pavia, Italy). They were used in the BaF-
B03 proliferation assay. BaF-B03-B2B2 cells grow in suspension and were 
maintained by diluting them 1:10-20 every 2-3 days.  
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Whenever cells were needed for an experiment or for transfection, their 
cell concentration had to be determined. For this purpose some of the cells 
were mixed with 0.4% Trypan blue stain, which stains dead cells, and 
counted on a Neubauer counting chamber. 
Table 5: Composition of culture media and other solutions needed for cell culture. Everything was kept 
sterile. 
BaF-B03 culture medium RPMI-1640 containing 
 10% foetal calf serum (FCS), 10% horse serum (HS)  
 100 U/ml penicillin, 100 µg/ml streptomycin 
 4 mM L-glutamine  
 100 ng/ml recombinant hGH (rhGH, IRP 88/624) 
Geneticin, 50 mg/ml  1 g geneticin in 20 ml sterile ddH2O 
 filtrated with a 0.2 µm filter 
 stored in -20°C 
HEK-293 culture medium DMEM containing 
 10% FCS 
 50 µg/ml Gentamicin 
 4 mM L-glutamine, 1 mM pyruvate  
HEK-293-GHR culture me-
dium 
DMEM:F12 containing 
 10% FCS 
 100 U/ml penicillin and 100 µg/ml streptomycin 
 2 mM L-glutamine 
 15 mM HEPES  
 400 µg/ml geneticin 
PBS  1 PBS tablet per 500 ml ddH2O 
 autoclaved 
 stored at 4°C 
3.3 Production of recombinant GH 
HEK-293 cells were used for production of wt and mutant GH. The cells 
were transiently transfected with the pcDNA3.1-GH constructs and con-
sequently, due to the signal sequence, GH was secreted in the medium. 
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The medium was collected and presence of GH was verified by Western 
blot and time-resolved immunofluorometric assays (TR-IFMAs). As soon 
as GH production could be confirmed, stable transfections were done in 
order to obtain wt or mutant GH producing cell lines.   
3.3.1 Transfection 
HEK-293 cells were transfected with the pcDNA3.1-GH constructs, using 
Lipofectamine™ 2000 as transfection reagent. The cells were seeded on the 
day before transfection according to table 6. In the same table are summa-
rized the needed amounts of media, DNA and lipofectamine for different 
culture dish formats. Both DNA and lipofectamine were diluted in Opti-
MEM® I Reduced Serum Medium. Diluted lipofectamine was incubated 
for 5 min at RT before mixing it with the diluted DNA. The mixture was 
then incubated for 20 min at RT, after which it was dropwise pipetted onto 
the cells. 24 h post transfection the medium was changed into 
Biowhittaker® Pro293a-CDM medium supplemented with 4 mM L-
glutamine, 1 mM pyruvate and 50 µg/ml Gentamicin. The medium, where 
GH was being secreted, was harvested 3 days later for experiments. Me-
dium from nontransfected cells was used as negative control in bioassays. 
Table 6: Transfection with Lipofectamine™ 2000.  
cell culture 
dish 
cells plating 
medium 
DNA in media 
volume 
Lipofectamine in 
media volume 
24-well plate 1x105 0.5 ml 0.8 µg in 50 µl 2 µl in 50 µl 
12-well plate 2x105 1 ml 1.6 µg in 100 µl 4 µl in 100 µl 
6-well plate 5x105 2 ml 4 µg in 250 µl 10 µl in 250 µl 
75 cm2 flask 2x106 10 ml 8 µg in 500 µl 20 µl in 500 µl 
3.3.1.1  Creation of stable cell lines 
HEK-293 cells on a 24-well plate were transfected with wt or mutant GH-
containing plasmids as described above. After 24 h the cells were passaged 
3 Material and methods 
 36 
1:10 and on the following day 0-1000 µg/ml geneticin was added per well. 
The neomycin gene that the pcDNA3.1 plasmid carries (see figure 14) pro-
vides resistance against the antibiotic geneticin, also known as G418, in 
eukaryotic cells [Wagman, 1980]. Once selection started to show, individ-
ual colonies were picked and seeded on a 24-well plate. The cells were fur-
ther cultivated in presence of 1000 µg/ml geneticin and finally the cells 
producing highest amount of recombinant GH were chosen for larger cul-
tures with reduced geneticin concentration (500 µg/ml). 
3.3.2 Separation of ∆188-190 monomer and dimer 
Δ188-190 was expressed mainly as a mixture of monomer and dimer. In 
order to do experiments with exclusively dimer, dimer and monomer were 
separated. This was done by Dr. Zida Wu, but here is a brief description. A 
large amount of the mutant GH was produced by culturing the Δ188-190-
expressing HEK-293 cell line in a miniPERM cell culture module. The mu-
tant-containing supernatant was concentrated with Roti-Spin MINI 3 col-
umns and then applied into a Superdex 75 column. Dimer and monomer 
were separated by size exclusion using a FPLC system. PBS was used for 
elution and 250 µl fractions were collected. Concentrations of the fractions 
were measured by TR-IFMAs (see chapter 3.3.3.2) and the fractions con-
taining monomer on one hand and dimer on the other were pooled to-
gether. Presence of monomer vs. dimer was confirmed in Western blot. 
Finally the samples were sterile filtered using a 0.2 µm filter. 
3.3.3 Confirmation of expression 
Cell supernatants from transient transfections or stable cell lines were ana-
lysed qualitatively by Western blot and quantitatively by TR-IFMAs. 
These methods were also used to verify the separation of Δ188-190 mono-
mer and dimer and to measure their concentrations.  
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3.3.3.1 Western blot 
Western blot was done in order to verify that GH is in fact secreted in the 
growth medium, has the expected size and to see if it’s forming dimers or 
oligomers.  
3.3.3.1.1 Procedure 
Table 7: Working solutions for Western blotting. 
SDS-PAGE gel 
(enough for two 12% 0.75 mm 
gels) 
 
Resolving gel  
2.5 ml 3 M Trizma® base, pH 8.8 (HCl) 
100 µl 20% SDS (w/v) 
4 ml 30% Acrylamide/Bis Solution 
3.3 ml ddH2O 
50 µl 10% APS (w/v) 
5 µl TEMED  
 
Stacking gel 
2.5 ml 0.5 M Trizma® base, pH 6.8 (HCl) 
50 µl 20% SDS 
1.3 ml 30% Acrylamide/Bis Solution 
6.09 ml ddH2O 
50 µl 10% APS 
10 µl TEMED 
SDS-PAGE 10x running buffer  0.25 M Trizma® base, 1.92 M glycine, 1% SDS, 0.01% 
NaN3 
 diluted 1:10 before use 
Towbin buffer  25 mM Trizma® base, 192 mM glycine, 20% MeOH 
in ddH2O 
PBS-Tween  1 PBS tablet per 500 ml ddH2O 
 0.05% Tween® 20 added 
Either reducing or non-reducing Lane Marker Sample Buffer was added to 
the supernatant and the proteins were separated by 12 % SDS-PAGE. Ka-
leidoscope Prestained Protein Standard was used as size reference. The 
samples were first stacked for 15 min at 70 V and then separated for 90 
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min at 110 V in 1x running buffer. The separated proteins were transferred 
into a nitrocellulose membrane between sheets of blotting paper, all wet-
ted in Towbin buffer using a Trans-Blot® Semi-Dry Electrophoretic Trans-
fer Cell. Thereafter, in order to prevent subsequent unspecific antibody 
binding, the membrane was blocked with 5% skim milk in PBS-Tween ei-
ther o/n at 4°C or for 1 h at RT under agitation on a rocking platform.  
After blocking and also later on, after both antibody incubations, the 
membrane was washed thoroughly with PBS-Tween. As primary antibody 
a mixture of two in-house monoclonal α-hGH antibodies, 10A7 [Gertler, 
1996] and 7B11 [Strasburger, 1996], was used, both diluted to 1µg/ml in 
0.5% skim milk/PBS-Tween. Secondary antibody was a sheep-derived, 
horseradish peroxidase (HRP)-labelled α-mouse antibody, diluted to 0.5 
µg/ml in 0.5% skim milk/PBS-Tween. Both incubations were carried out 
for 1 h at RT under agitation. Finally, the bands were visualized in an en-
hanced chemiluminescence (ECL) reaction using Amersham ECL™ West-
ern Blotting Detection Reagents. The light reaction was captured on Amer-
sham Hyperfilm and the film was developed using an automated Curix 60 
table-top processor. 
3.3.3.2 TR-IFMA 
TR-IFMAs employing different in-house monoclonal antibodies (mAbs) 
were used for determination of GH concentration in media. Biotinylated 
10A7 (10A7-b) was always used as tracer antibody (mAb2-b in figure 16) 
and three different mAbs, named 7B11, 8B11, 6C1 [Thorner, 1999] and 1B3 
[unpublished], were used as capture antibodies (mAb1 in figure 16) de-
pending on the mutation in question. 7B11, 8B11 and 6C1 gave an ap-
proximately same concentration for wt GH. 7B11 or 8B11 was used when 
C182A, C189A and C182+9A were measured. 8B11 was used for R77C and 
D112G because 7B11 appeared to bind particularly strongly to D112G giv-
ing a false concentration. 6C1 was used for ∆188-190 and its monomeric 
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and dimeric forms since it can equally measure dimer and monomer. 1B3 
recognises preferentially dimeric GH and was therefore used to measure 
the degree of dimerization. Binding epitopes of the used mAbs except for 
1B3 can be found in appendix VI [Wu, 1998]. Generation and biotinylation 
of antibodies had been done by Dr. Zida Wu as described by Strasburger 
et al. [1996]. The hGH standard used in this assay was pituitary hGH 
(phGH; IRP 80/505) which best resembles GH secreted by eukaryotic cells 
[Jansson, 1997].  
 
Figure 16: TR-IFMA. mAb1, which can be either 7B11, 8B11, 6C1 or 1B3, captures the GH (here 
in a random posture), to which the biotinylated tracer antibody 10A7-b binds. Europium (Eu)-
labelled streptavidin (Strep) binds to the biotin, and the europium can be measured in dissocia-
tion-enhanced time-resolved fluorometry. 
3.3.3.2.1 Procedure 
Table 8: Working solutions for TR-IFMA. 
Assay buffer  50 mM Trizma® base, 154 mM NaCl, 20 µM DTPA, 
0.01% Tween 40, 0.05% NaN3, 0.05% bovine γ-
globulin and  0.5% BSA in ddH2O 
 pH 7.75 
 filtration with 8 µm cellulose nitrate filter 
 storage at 4°C 
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Coating buffer  50 mM Na2HPO4 in ddH2O 
 pH 7.4 
Enhancement solution 
 
 
 
 
100x Enhancement solution I 
 100 mM thenoyltrifluoroacetone, 10 mM tri-n-
octylphosphinoxide, 2% EtOH and 20% Triton® X-
100 in ddH2O 
 storage at 4°C 
10x Enhancement solution II  
 68 mM KHP and 6% HAc in ddH2O 
 storage at 4°C 
Working solution 
 1 % Enhancement solution I mixed with 10 % En-
hancement solution II 
A 96-well flat bottom microtiter plate was coated with 500 ng mAb1 in 200 
µl coating buffer per well, covered with self-adhesive film and stored in 
4°C for a minimum of 12 h. The plate was washed with PBS-Tween after 
every incubation step, using a Columbus 12 Channel Head 96 well Strip 
Plate Washer.  Onto the mAb1-coated plate, 175 µl assay buffer per well 
was pipetted. To this, 25 µl phGH with increasing concentrations (0 to 100 
ng/ml) or 25 µl sample, both diluted in assay buffer, was added and the 
plate was incubated for 2 h. In all incubation steps of this and other im-
munoassays the plate was agitated on a DELFIA® Plate Shaker at RT if not 
otherwise specified. A subsequent 2 h incubation was done with 50 ng bio-
tin-labelled mAb 10A7 (10A7-b=mAb2-b in figure 16) in 200 µl assay 
buffer per well. In the following steps the plate was first incubated with 
europium-labelled streptavidin (streptavidin-Eu) and then with enhance-
ment solution as described in figure 17. Fluorescence signal was read on 
VICTOR3TM Multilabel Counter. Based on the phGH standard curve, con-
centrations of samples were calculated automatically by Multicalc pro-
gram. 
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Figure 17: Finishing a TR-IFMA. This procedure was used in all fluorometric assays of this project. 
The plate was first incubated for 30 min with 20 ng streptavidin-Eu in 200 µl assay buffer per well 
then for 10 min with 200 µl enhancement solution per well. In the competitive GHBP binding 
assay (chapter 3.4.1.2) the amounts of streptavidin-Eu, assay buffer and enhancement solution 
were halved, i.e. 10 ng streptavidin-Eu, 100 µl assay buffer and 100 µl enhancement solution per 
well. Finally the fluorescence was read on VICTOR3TM Multilabel Counter. 
3.4 Functional and structural characterization of recombinant 
GH 
The supernatants with known GH concentrations were used for an array 
of experiments in order to gain information about the binding affinity, bio-
logical activity and stability of the different mutant GHs in comparison to 
wt GH.  
3.4.1 Binding studies 
First of all the binding affinity was investigated with two immunoassays 
employing GHBP. For studies with full-length hGHR, the HEK-293-GHR 
cell line and radioactive 125I-hGH were utilized.  
3.4.1.1 Immunofunctional assay 
With this sandwich assay the functionality of both binding sites of the mu-
tants compared to wt hGH could be studied. The assay has been devel-
oped by Strasburger et al. [1996 & 1999]. 7B11, which recognizes binding 
site 2 of hGH, is used as capture antibody and biotin-labelled recombinant 
hGHBP (GHBP-b), which in this case binds to binding site 1, as tracer. 
Unlike in the TR-IFMAs, rhGH (IRP 88/624) was used as standard. The 
assay is elucidated in figure 18. 
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Figure 18: Immunofunctional assay. The assay scheme is similar to the one described in figure 10. 
The green binding site 2 of GH is recognized by the mAb 7B11 and the blue binding site 1 binds 
to a biotinylated GHBP molecule. 
3.4.1.1.1 Procedure 
The plate was coated with 500 ng mAb 7B11 in 200 µl coating buffer per 
well, just like in the TR-IFMA (chapter 3.3.3.2). After a wash step, 175 µl 
assay buffer and 25 µl sample or standard was added per well and the 
plate was incubated for 3 h. Incubation with 25 ng GHBP-b in 200 µl assay 
buffer per well took place o/n at 4°C. GHBP had been a gift from Professor 
Gertler (Rehovot, Israel) and it was biotinylated by Dr. Zida Wu as de-
scribed by Strasburger et al. [1996]. The assay was finished as described in 
figure 17. The immunofunctional concentration was calculated by the Mul-
ticalc program based on rhGH standard curve. An immunofunctional 
proportion was obtained by comparing this immunofunctional concentra-
tion to the one measured by TR-IFMA. 
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3.4.1.2 Competitive GHBP binding assay 
Cross-reactivity is an indicator of binding affinity. Thus a competitive as-
say where labelled GHBP bound to GH is displaced by increasing concen-
trations of unlabelled GHBP gives a good idea of GH’s binding affinity to 
GHBP. Since GHBP equals to the extracellular domain of full-length recep-
tor, one can from this assay also quite well predict GH’s binding affinity to 
GHR. 
First step was to determine a concentration for each sample where the ob-
tained fluorescence would correspond to approximately 10% of maximal 
fluorescence measured with wt GH. A sandwich assay employing mAb 
10A7 and GHBP-b was used for this purpose. 10A7 recognises an epitope 
far from both binding sites and thus leaves them available for GHBP. In 
the subsequent assay GHBP and GHBP-b compete for 10A7-bound GH. 
The assay is illustrated in figure 19. 
 
Figure 19: GHBP binding assay. In the pre-assay only GHBP-b is let bind to GH but in the final 
assay GHBP-b competes with increasing concentrations of unlabelled GHBP. Streptavidin-Eu is 
again used for detection.   
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3.4.1.2.1 Procedure – step 1 
Same solutions as in TR-IFMA were used (see table 8). 75 µl assay buffer 
and 25 µl sample were pipetted to the wells of a 96-well plate coated with 
500 ng mAb 10A7 in 100 µl coating buffer per well. Sample was either 0 to 
1000 ng/ml wt GH for the definition of maximal signal or 0 to 100 ng/ml 
GH in cell supernatant for definition of the 10% maximum. All samples 
were diluted in assay buffer. After incubating the plate for 2 h with the 
samples, 10 ng GHBP-b in 100 µl assay buffer per well followed. After an-
other 2 h incubation the assay was finished as in figure 17, but with halved 
amounts. Fluorescent counts were plotted against hGH concentration (MS 
Office Excel) and the concentration at 10% of maximal counts measured 
with wt GH was calculated for each sample. A trend line was inserted for 
the linear part of the curve and the appropriate concentration was calcu-
lated with the formula of the trend line. 
3.4.1.2.2 Procedure – step 2 
Onto a 96-well plate coated with 10A7 as in step 1, 75 µl assay buffer and 
25 µl sample with the concentration calculated above were pipetted, two 
rows per sample. After incubating for 2 h, GHBP and GHBP-b followed. 
First 50 µl 0 to 1000 ng/ml unlabelled GHBP (diluted in assay buffer) was 
pipetted to each pair of rows, and then 10 ng GHBP-b in 50 µl assay buffer 
was added to all wells. The assay went on as described in figure 17, but 
with half the amounts of buffer and streptavidin-Eu. Acquired counts 
were divided by the counts of the same GH molecule at 0 ng/ml GHBP, 
and this so called B/B0 value was plotted against the increasing GHBP 
concentration, whereby a sigmoidal curve was obtained. The curve was 
analysed with GraphPad Prism 5.01 by nonlinear regression using the 
sigmoidal dose-response equation. The greater the concentration of unla-
belled GHBP required for displacement of 50% of GHBP-b, i.e. the IC50 
value, the lower the binding affinity of the GH molecule in question.  
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3.4.1.3 GHR binding assay 
In order to examine GH binding to full-length receptor, an assay exploit-
ing 125I-labelled GH and HEK-293 cells stably transfected with full-length 
human GHR (HEK-293-GHR) was performed. Similarly, as in the previous 
experiment, the biotin-labelled GHBP bound to GH was displaced by in-
creasing concentrations of unlabelled GHBP, here radioactively labelled 
GH is displaced by increasing concentrations of sample GH on a 
monolayer of GHR-expressing cells. 
3.4.1.3.1 Procedure 
Table 9: Binding buffer for GHR binding assay. 
Binding buffer 4x stock: 
 5.36 mM KCl, 0.44 mM KH2PO4, 0.3343 mM Na2HPO4x12H2O, 
5.55 mM glucose 
 pH 7.4 
Working solution:  
 1.3 mM CaCl2, 280 mM sucrose, 0.2% BSA and 2.5% skim milk in 
1x stock solution  
75,000 HEK-293-GHR cells per well on a 48-well plate were seeded and let 
attach o/n. On the following day the cells were first washed with binding 
buffer. Then 100 µl of 0 to 20 nM GH diluted in binding buffer and 60,000 
cpm of 125I-hGH in 100 µl binding buffer were added to each well and the 
plate was again incubated o/n. To finish the assay, the cells were washed 
twice with ice cold binding buffer after which 500 µl 0.1 M NaOH was 
added and counts were measured. The higher the counts were, the less 
sample GH had bound to the cells and thus the lower its binding affinity 
to GHR was. The counts of each sample were divided by counts at 0 nM 
GH. These B/B0 values were plotted against GH concentration and IC50 
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values based on fitted sigmoidal dose-response curves were calculated 
with GraphPad.  
3.4.2 Bioassays 
Biological activity of the mutants was studied by two assays – BaF-B03 
assay measuring their proliferative potential and STAT5 assay determining 
their ability to initiate signal transduction. In order to rule out any effect of 
the cell supernatant per se, a sample from cells that had been “transfected” 
without plasmid was included as control. It was diluted as the GH sample 
with lowest GH concentration, i.e. with highest content of serum-free me-
dium. 
3.4.2.1 BaF-B03 proliferation assay 
BaF-B03 is a mouse IL3-dependent pro-B cell line isolated from the paren-
tal Ba/F3 cells [Hatakeyama, 1989; Palacios, 1985]. Behncken et al. [1997] 
were the first to stably transfect these cells with hGHR for their GH bind-
ing studies. Rowland et al. [2002] used identical cells, naming them clone 
B2B2, for a proliferation assay measuring GH bioactivity. BaF-B03-B2B2 
cells can be maintained with hGH instead of IL3. Proliferation assays for 
hGH have also been applied by Yoshizato et al. [2000] and Ishikawa et al. 
[2000] but they used the parental Ba/F3 cells instead of the subclone BaF-
B03. We used the assay developed by Rowland et al. [2002] as basis for our 
proliferation assay. 
3.4.2.1.1 Procedure 
Table 10: Starvation medium for BaF-B03 proliferation assay. 
BaF-B03 starvation medium RPMI-1640 containing 
 0.5% HS  
 100 U/ml penicillin, 100 µg/ml streptomycin 
 4 mM L-glutamine  
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Luciferase, Mg2+ 
===========> 
The BaF-B03-B2B2 cells were cultivated as described in chapter 3.2. Once 
cell density was about 50,000-100,000 cells/ml, the cells were washed with 
PBS and starved o/n in growth medium without rhGH and FCS and only 
0.5% HS (starvation medium). On the following day, the cells were again 
washed with PBS, and then 25,000 cells in 50 µl starvation medium per 
well were pipetted on a white 96-well flat bottom cell culture plate. Wt 
and mutant hGH were diluted in starvation medium and added to the 
wells as additional 50 µl. The plate was incubated for 24 h, after which the 
cells were lysed and their ATP content was measured using the ViaLight® 
Plus Kit. The method is based on the following reaction:  
ATP + Luciferin + O2                                  Oxyluciferin + AMP + PPi + CO2 + light 
The obtained luminescence was measured on VICTOR3TM Multilabel 
Counter. ATP concentration is considered to be a reliable reference for cell 
number [Dexter, 2003]. In order to be able to compare results from sepa-
rate experiments with each other, the luminescence of each sample was 
divided with luminescence of wt at 5 nM. This “total of wt(max)” was 
plotted against GH concentration and EC50 values for wt and mutants 
were calculated based on a fitted sigmoidal dose-response curve using 
GraphPad.  
3.4.2.2 STAT5 transcription assay 
STAT5 transcription assay is a tool to quantify activation of the Jak/STAT 
signalling pathway by GH (see chapter 1.1.6.2.1). This is achieved by trans-
fecting HEK-293-GHR cells with a plasmid containing a lactogenic hor-
mone responsive element (LHRE) fused to a minimal thymidine kinase 
(TK) promoter and firefly luciferase. STAT5 binding to LHRE leads to syn-
thesis of luciferase which can be detected as the amount of substrate that is 
converted to product in a light-producing reaction. Dexamethasone is 
added to the stimulation medium because it enhances GH-induced activa-
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tion of LHRE [von Laue, 2000]. In order to take transfection efficacy into 
account, a second plasmid containing the gene for renilla luciferase under 
the control of a constitutively active cytomegalovirus (CMV)-promoter 
was included in the transfection. Since these two luciferases have different 
substrates, the luminescence they produce can be detected in two separate 
reactions and the firefly luciferase activity can be normalised to renilla 
luciferase activity. This was done using the Dual-Luciferase® Reporter 
(DLR™) Assay System. The reactions catalysed by the firefly and renilla 
luciferases are shown in figure 20.  
 
Figure 20: Reactions catalysed by firefly and renilla luciferases with beetle luciferin and coelenterazine 
as respective substrates. Assay reagents contain the substrates whereas the luciferases are encoded 
by the plasmids, with which the cells have been transfected [Promega’s Dual-Luciferase® Re-
porter 1000 Assay System, Technical Manual].  
STAT5 transcription assay was developed by Ross et al. and the first ver-
sion was published in 1997. They further developed the assay over years 
[Maamra 1999, Ross 2001] and kindly provided us the needed cells and 
plasmids. I adapted the assay from 6-well to 96-well format, changed 
transfection reagent from calsium phosphate to Lipofectamine™ 2000 and 
increased relative LHRE concentration fivefold for higher signal.  
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3.4.2.2.1 Procedure 
Table 11: Media for STAT5 transcription assay. 
Rich medium  1 part HEK-293 culture medium mixed with 2 parts 
HEK-293-GHR culture medium 
Stimulation medium DMEM:F12 containing 
 100 U/ml penicillin and 100 µg/ml streptomycin 
 2 mM L-glutamine 
 15 mM HEPES  
 100 ng/ml dexamethasone 
 1% BSA 
A ca 80% confluent flask of HEK-293-GHR cells was incubated for 6 h in 
rich medium. After this, 15,000 cells in 100 µl rich medium per well were 
seeded on a white 96-well flat bottom cell culture plate. The cells were 
then transiently transfected with LHRE/TK-luciferase reporter gene con-
struct and phRL-CMV plasmid.  
DNA mix Transfection mix 
38 ng LHRE/TK-luciferase reporter gene construct 
150 pg phRL-CMV 
92 ng salmon sperm (for 130 ng total DNA) 
Opti-MEM® up to 25 µl 
Lipofectamine 2000 diluted 1:50 
 5 min at RT 
25 µl diluted lipofectamine + 25 µl DNA 
mix 
 20 min at RT 
 
50 µl transfection mix was slowly pipetted into each well of cells. On the 
following day the cells were stimulated for 6 h with increasing amounts of 
wt or mutant hGH in 50 µl stimulation medium. Supernatant from cells 
transfected without plasmid was again used as control in order to rule out 
the possibility that the medium alone could activate the STAT5 pathway. 
Finally cells were lysed with 1x Passive Lysis Buffer (DLR™ kit) and their 
firefly (LHRE) and Renilla (phRL-CMV) luciferase activities were meas-
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ured with Mithras LB 940 luminometer and MicroWin 2000 software. The 
course of the DLR™ assay procedure is summarized in figure 21.  
 
Figure 21: Measurement of the transcription assay. All steps were done at RT. Luciferase Assay 
Reagent II (LAR II) and Stop & Glo Reagent were always prepared fresh by mixing substrate with 
appropriate buffer. Further details can be found in the Technical Manual of the DLR™ Assay Sys-
tem. 
Normalised firefly/Renilla luciferase activity was further divided by 
maximal activity of wt/rhGH so that the separate experiments could be 
compared with each other despite of the differences in minimal and 
maximal activities between assays. The obtained “total of wt/rhGH(max)” 
values were plotted against GH concentration using GraphPad. 
3.4.2.3 Inhibitions  
Antagonistic effect of Δ188-190 dimer and monomer was studied in both 
bioassays. In that case the sample was 25 µl rhGH with a constant concen-
tration and 25 µl Δ188-190 dimer or monomer with an increasing concen-
tration. B2036 was used as a positive inhibition control. B2036 is the GHR 
antagonist Pegvisomant without PEG-residues. The obtained lumines-
cence counts from BaF-B03 assay and normalised Renilla/firefly luciferase 
activities were divided by the values obtained with only rhGH. These B/B0 
values were plotted against the molar ratio of antagonist and rhGH 
(GraphPad). 
3.4.3 Stability studies 
Both methods applied for stability studies are based on the drop in GH 
concentration due to exposure to degrading substances – in the first ex-
3 Material and methods 
 51 
periment substances naturally present in human serum and in the second 
one the digestive enzyme trypsin.  
3.4.3.1 Incubation in serum 
GH-containing supernatants were diluted in human serum with *GH+ ≤ 
0.2 ng/ml and incubated for 24 or 144 h at 37°C with gentle agitation on 
Eppendorf Thermomixer 5436. Samples were collected at different time 
points and stored in -20°C until analysis. GH concentrations were meas-
ured by TR-IFMA as described in chapter 3.3.3.2 but the samples and 
standard phGH were diluted in sheep serum instead of assay buffer. 1B3 
and 6C1 were used for dimeric ∆188-190 and 7B11 and 8B11 for other 
samples. The resulting concentrations were compared to the ones at at t(0). 
3.4.3.2 Trypsin digestion 
Table 12: Trypsin solution for stability studies. 
Trypsin, 100 µg/ml  0.1 mg trypsin dissolved in 1 ml 1 mM HCl 
 storage in -20°C 
 working solution 1:100 in 1 mM HCl 
Wt and mutant hGH were diluted to 500 ng/ml in the serum-free 
Biowhittaker® Pro293a-CDM medium, in which they had been harvested 
as well (see chapter 3.3.1). A 100 µg/ml trypsin stock solution was diluted 
1:100 with 1 mM HCl to achieve a 1000 ng/ml dilution. 12 µl of this trypsin 
dilution or 12 µl 1 mM HCl for negative control was added to 120 µl of the 
500 ng/ml GH dilution and the mixture was incubated for 2 h at 37°C with 
gentle agitation on Eppendorf Thermomixer 5436. Samples were collected 
at different time points and analysed by Western blot in reducing condi-
tions (see chapter 3.3.3.1). 
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4 Results 
GH mutants R77C, D112G, C182A, C189A, C182+9A and ∆188-190 pro-
duced in eukaryotic cells were characterized in comparison to wt GH in an 
array of in vitro experiments. All graphs and statistical analysis were per-
formed with GraphPad Prism 5.01 unless otherwise stated. Observed dif-
ferences between wt and mutant GH were analysed by unpaired t-test 
with Welch’s correction (*p < 0.05, **p < 0.01, ***p < 0.001). 
4.1 Construction of expression plasmids 
 
Figure 22: Construction of expression plasmids. A. Expected sizes of first-step PCR products were 
316 bp for GH-fwd & R77C-rev, 365 bp for R77C-fwd & GH-rev, and 649 bp for GH-fwd & ∆188-
190-rev. After purification, concentrations of the first PCR products were determined by running 
2 µl PCR product and 0.5 µl Low DNA Mass ladder on 1% agarose gel. Estimated concentrations 
were ~5 ng/µl for GH-fwd & R77C-rev, ~10 ng/µl for R77C-fwd & GH-rev and ~2.5 ng/µl for GH-
fwd & ∆188-190-rev (ladders in appendix VII). B. Second-step PCR with the GH-fwd & R77C-rev 
and R77C-fwd & GH-rev fragments using GH-fwd and -rev primers resulted in a 658 bp band and 
several by-products. The most intense band was purified. C. Midipreps pcDNA3.1-R77C and -
∆188-190 were digested with BglII & BamHI and with EcoRV & HindIII. Expected sizes with BglII & 
BamHI were 506, 908 and 4754/4745 bp (the latter size for ∆188-190), and with EcoRV & HindIII 
714/705 and 5454. 
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Mutations R77C, D112G, C182A, C189A, C182+9A and ∆188-190 were in-
troduced into the GH-1 gene by site-directed mutagenesis. In figure 22, 
R77C is presented as an example for two-step and ∆188-190 for one-step 
mutagenesis. Fragment sizes of ladders are displayed in appendix VII. The 
obtained cDNA for wt or mutated GH-1 was cloned into expression vector 
pcDNA3.1. Resulting plasmids were first purified in small-scale in order 
to find correct constructs by restriction analysis with BglII & BamHI and 
HindIII & EcoRV. One of these “minipreps” was then chosen for a larger 
culture, resulting in “midipreps”. The correctness was again checked by 
restriction analysis (figure 22C) and after that further verified by sequenc-
ing.  
4.2 Expression of recombinant GH in HEK-293 cells 
Recombinant GH was produced by transfecting HEK-293 cells with the 
midipreps whose correct sequence had been confirmed. GH was secreted 
in serum-free growth medium, which was used for experiments. GH con-
centrations were determined by TR-IFMAs. Numerous transfections were 
done and some typical GH concentrations, usually from 1000 to 2000 
ng/ml, can be seen in table 13.  
Stable HEK-293 cell lines were created for production of wt and mutant 
GH. For this purpose the cells were further cultured after transfection and 
cells carrying the expression plasmid were selected using the antibiotic 
geneticin. Stable cell lines turned out rather ineffective in GH production, 
usual TR-IFMA concentrations being 100-300 ng/ml. Because of the higher 
concentration and also because GH in serum-free medium was preferred 
for bioassays, GH produced by transient transfection was used for ex-
periments. The ∆188-190 cell line was an exception since it was used for 
the production of the mutant’s monomeric and dimeric forms. For this 
purpose vast amounts of the ∆188-190 mutant were needed and since dur-
ing fractionation and purification it was concentrated and the medium 
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was changed, the low concentration and serum-containing medium were 
not a problem.  
In Western blot the correct size of the recombinant GH was verified and 
also the concentrations measured by TR-IFMAs were checked for plausi-
bility. Successful separation of ∆188-190-monomer and -dimer could also 
be seen in Western blot. In figure 23, 2.5 ng mutant or wt GH in either non-
reducing or reducing buffer was loaded per lane on 12% SDS-PAGE gel. 
phGH was included as control.  
 
Figure 23: Western blot. 2.5 ng of sample in either non-reducing or reducing buffer was blotted. 
All samples seem to have the correct 22 kD size. Mutants ∆188-190, C182A and C189A with a 
free C-terminal cysteine form an oligomer, probably trimer, that cannot be seen in the other sam-
ples. Some 44 kD dimer is present in all non-reduced samples except for the ∆188-190-monomer. 
Mutants with a free cysteine are the ones with most dimer. In phGH, ∆188-190 and ∆188-190-
dimer some dimer is left even in reducing conditions. ∆188-190-monomer is only present as a 
faint band in reducing buffer. 
Size of recombinant monomeric GH is 22 kD. Sizes and approximate con-
centrations of wt and all mutants seem correct when compared to phGH 
and a size standard. In non-reducing buffer ∆188-190-dimer has the correct 
44 kD size. Some dimer is present in all samples except for the ∆188-190-
monomer. In all samples with a free cysteine, i.e. ∆188-190, C182A, C189A 
and R77C, also a bigger band – probably a trimer – can be seen. In these 
mutants also dimer formation is more prominent. Some dimer is left of 
phGH and, to less extent, of ∆188-190 and ∆188-190-dimer even in reduc-
ing buffer. Monomeric ∆188-190 is apparently degraded in reducing buffer 
and only a faint band is left. 
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4.3 Binding affinity 
Once production of recombinant GH had been confirmed and the GH 
concentration of supernatants had been quantitatively determined, the 
actual characterization of the mutants began. One important aspect of GH 
functionality is its binding to the GH receptor. This was studied by three 
experiments, two of which were immunoassays based on GH binding to 
GHBP, which equals the extracellular domain of GHR. In the third ex-
periment binding to full-length GHR on eukaryotic cell surface was exam-
ined. 
4.3.1 Determination of immunofunctional concentration  
A so-called immunofunctional concentration was determined with an im-
munoassay employing GHBP and the mAb 7B11. A concentration similar 
to the one measured by TR-IFMA requires that both GH binding sites are 
unaltered. In this assay rhGH instead of the usual immunoassay standard 
phGH was used since rhGH contains exclusively the 22 kD isoform of GH 
molecules fulfilling the prerequisite to be recognised by the combination 
of mAb 7B11 and GHBP-b. This is the reason why even concentration of 
wt GH is somewhat lower in the immunofunctional assay when compared 
to the TR-IFMA – approximately 80%. D112G binds to the mAb 7B11 with 
higher affinity than wt GH, which explains its high immunofunctional 
proportion, 97.2% (table 13C). The mutants that showed a much lower 
immunofunctional proportion than wt GH were ∆188-190 (table 13A), 
C182A, C189A and C182+9A (table 13B). Their immunofunctional propor-
tions were only 4.1-25.6%. R77C was similar to wt with its 78.2% (table 
13C).  
4 Results 
 56 
Table 13: Immunofunctional concentrations. Based on the integrity of both binding sites, an im-
munofunctional concentration was determined for the GH mutants. Wt measured in the same 
assay (A-C) was always included in the results. Samples with quite a low immunofunctional pro-
portion are highlighted in the table. These include C182A, C189A, C182+9A and ∆188-190. R77C 
is similar to wt and, due to high binding affinity to mAb 7B11, D112G has a somewhat higher 
immunofunctional proportion than wt.  
 Sample 
TR-IFMA concen-
tration (ng/ml) 
Immunofunctional con-
centration (ng/ml) 
Immunofunctional 
proportion 
A 
wt 1380 1140 82.6% 
∆188-190 1720 70 4.1% 
B 
wt 2530 2020 79.8% 
C182A 3060 556 18.2% 
C189A 2130 163 7.7% 
C182+9A 2940 752 25.6% 
C 
wt 2590 2040 78.8% 
R77C 1040 813 78.2% 
D112G 2510 2440 97.2% 
4.3.2 Binding to GHBP 
GH binding to GHBP was studied by an immunoassay, where biotin-
labelled and unlabelled GHBP competed for the GH binding sites. GH was 
first bound to immobilized mAb 10A7, which binds GH far from both 
binding sites (appendix VI), leaving them exposed for GHBP. Before the 
competitive GHBP assay was started, the wt GH concentration at which 
maximal GHBP-b binding was achieved was determined. GH concentra-
tion at 10% of this maximum would be used in the competitive assay. This 
way the starting situation would be the same for wt and each mutant GH. 
Two maximums, 968,000 and 1,640,000 counts, were determined using two 
different GHBP-b stocks. In both cases concentration of wt GH was 500 
ng/ml wt GH (figure 24A). 100,000 and 160,000 counts, which were ap-
proximately 10% of maximum, were chosen as target signals.  
In order to determine the concentration at 100,000/160,000 counts for the 
mutants, 0-100 ng/ml of the GH being tested was assayed and the obtained 
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counts were plotted against the GH concentration. A trend line was fitted 
to the curve (not included in figures 24B-D) and the concentration at 
100,000/160,000 counts was calculated with its equation.  
 
Figure 24: Competitive GHBP binding assay – step 1. 10% of maximal binding by wt was deter-
mined for each mutant. A. As marked with a dashed red line, maximal GHBP-b binding with wt 
GH was achieved at 500 ng/ml and resulted in 968,000 or 1,640,000 counts, depending on the 
used GHBP-b stock. Concentration at 100,000/160,000 counts, which was approximately 10% of 
maximum, was used as assay concentration for wt and mutant GH. B. Concentrations at 100,000 
counts for wt and the mutants ∆188-190, C182A, C189A, R77C and D112G were 16, 33, 21, 20, 
16 and 16 ng/ml, respectively. C. When wt, C182A and C189A were compared with the double-
mutant C182+9A, the concentrations at 160,000 counts were 13 ng/ml for wt, 17 ng/ml for 
C182A, 20 ng/ml for C189A and 14 ng/ml for C182+9A. D. ∆188-190-monomer and -dimer were 
compared to phGH. At 160,000 counts the concentration of phGH was 14 ng/ml and of ∆188-
190-monomer 35 ng/ml. ∆188-190-dimer bound GHBP very poorly and one would theoretically 
need 2800 ng/ml of it in order to achieve 160,000 counts. 
In figure 24B concentration of wt GH at 100,000 counts was 16 ng/ml. Cor-
responding concentrations of R77C and D112G were 16 ng/ml as well, but 
those of C182A and C189A were somewhat higher, both 20 ng/ml. ∆188-
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190’s concentration at 100,000 counts was 33 ng/ml. Later on when the as-
say was repeated with C182A and C189A together with C182+9A (figure 
24C), the concentrations at 160,000 counts were 13 ng/ml for wt, 17 ng/ml 
for C182A, 20 ng/ml for C189A and 14 ng/ml for C182+9A. As can be seen 
in figure 24D, ∆188-190-dimer did not bind to GHBP almost at all. Theo-
retically, one would have needed a 2800 ng/ml dilution of ∆188-190-dimer 
to achieve 160,000 counts. This concentration for ∆188-190-monomer was 
35 ng/ml and for phGH 14 ng/ml. This preliminary step remained the only 
result for ∆188-190 dimer and monomer. The concentration at 
100,000/160,000 turned out to correlate well with GHBP binding affinity, so 
one can draw the conclusions that ∆188-190-dimer has an extremely low 
and ∆188-190-monomer a rather low binding affinity to GHBP in compari-
son to phGH. 
The freshly determined GH concentration at 100,000/160,000 counts was 
used in the competitive GHBP assay. IC50 values of the mutants were 
compared to a wt that had been assayed together with them. The obtained 
curves and IC50 values are presented in figure 25. In case of C182A and 
C189A, the results in figure B1 were used. The ones in figure B2 were ob-
tained with another GHBP stock, which had quite an influence on the ob-
tained curves and IC50 values.  
Four of the mutants, ∆188-190, C182A, C189A and C182+9A, displayed a 
significantly lower binding affinity to GHBP than wt GH. GHBP binding 
affinities of R77C and D112G differed slightly from wt (figure 25C) but the 
standard deviations were rather high, so the differences were not consid-
ered meaningful.  
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Figure 25: Competitive GHBP binding assay – step 2. The concentrations determined in step 1 
(figure 24) were used for the competitive assay. B/B0 values were plotted against GHBP concen-
tration. IC50 values were determined based on fitted sigmoidal dose-response curves, which are 
not included in the figures. A. IC50 value of the ∆188-190 mutant was significantly higher than 
that of wt GH. The data is from two separate experiments. B1. C182A, C189A and C182+9A 
show significantly higher IC50 values than wt GH. B2. Due to a different stock of unlabelled 
GHBP, C182A and C189A seemed more similar to wt – only C189A differed significantly from wt 
GH. C. No significant differences were detected between wt GH and the mutants R77C and 
D112G. The data is from three separate experiments in B1-C. 
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4.3.3 Binding to full-length GHR 
GH binding to full-length receptor on cell surface was measured by letting 
increasing amounts of wt or mutant GH compete with a constant concen-
tration of 125I-labelled hGH. HEK-293 cells stably transfected with GHR 
were used for this purpose. B/B0 values based on the radioactive counts 
were plotted against GH concentration. Sigmoidal dose-response curves 
were fitted to the resulting curves and IC50 values were calculated. As 
shown in figure 26, C182A and C189A have significantly higher IC50 val-
ues and thus bind less efficiently to GHR than wt GH. IC50 of ∆188-190 is 
quite high as well, but the difference is not significant. D112G has a very 
similar IC50 as wt. 
 
Figure 26: GHR binding assay. 125I-labelled GH and increasing concentrations of wt or mutant GH 
were let bind on HEK-293-GHR cells. B/B0 values were plotted against GH concentration. The 
dotted curves represent the actual measured values and the continuous ones are fitted sigmoidal 
dose-response curves. IC50s were calculated and those of the mutants were compared to wt. 
IC50s of C182A and C189A were significantly higher than that of wt. ∆188-190 had quite a high 
IC50 as well but the difference was not significant. Data from three separate experiments was 
used. 
4.4 Biological activity 
Two approaches were used as the biological activity of the mutants was 
studied. Their ability to induce cell proliferation was examined in BaF-B03 
cells stably transfected with GHR (clone B2B2), and their ability to induce 
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signal transduction by a STAT5 transcription assay employing HEK-293 
cells also stably transfected with GHR. In both assays supernatant from 
cells transfected without plasmid was used as control in order to ensure 
that the serum-free growth medium alone did not have the ability to in-
duce cell proliferation or signal transduction. 
4.4.1 Proliferative effect 
BaF-B03-B2B2 cells were starved o/n and then stimulated for 24 h with wt 
and mutant GH. Cell count was determined based on ATP content of sam-
ples in a luminescent reaction. Induction of proliferation relative to maxi-
mal induction by wt GH, the “total of wt(max)”, was plotted against GH 
concentration. Sigmoidal dose-response curves were fitted to the results 
and EC50 for wt and each mutant was calculated. Results are presented in 
figure 27. Proliferation induction by the supernatant control remains un-
der 7% and hence the proliferative effect is caused by GH only. One can 
see in figure 27A that the dose-response curves of ∆188-190 and C189A 
ascend somewhat later than the others, which are almost upon one an-
other. This difference is even more notable and also statistically significant 
in the calculated EC50 values (figure 27B). The other mutants did not dif-
fer much from wt GH. 
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Figure 27: BaF-B03 proliferation assay. BaF-B03-B2B2 cells stably transfected with GHR were 
stimulated for 24 h with wt or mutant GH. Amount of cells was determined by measuring ATP 
concentration in a luminescent reaction. A. Relative stimulation compared to wt(max) was plot-
ted against GH concentration. The supernatant (SN) control had no proliferative effect. Curves of 
wt, C182A, C182+9A, R77C and D112G are almost one upon each other but the ones of ∆188-
190 and C189A ascend slightly later, indicating a lower proliferative effect. B. Based on fitted sig-
moidal dose-response curves (not included due to similarity to the original curves in 27A), an 
EC50 value for each mutant was obtained. Two of the mutants, ∆188-190 and C189A, differed 
significantly from wt. Data from three separate experiments was used for analysis. 
Proliferative effects of ∆188-190-monomer and -dimer were compared to 
the IRP rhGH (produced in E. coli) instead of our wt GH produced in 
HEK-293 cells. Results are shown in figure 28. Much more ∆188-190-
monomer than rhGH is required for the same proliferative effect and 
dimeric ∆188-190 was even less efficient than monomer. 
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Figure 28: BaF-B03 proliferation assay with ∆188-190-monomer and -dimer. BaF-B03 cells expressing 
GHR were stimulated for 24 with rhGH, ∆188-190-monomer and ∆188-190-dimer. Cell content 
was determined based on [ATP] in a luminescent reaction. Relative induction compared to 
rhGH(max) was plotted against GH concentration. Proliferative effect of ∆188-190-monomer is 
much lower than that of rhGH and that of ∆188-190-dimer is yet lower. The data is from one 
experiment. 
4.4.2 Signal transduction 
HEK-293-GHR cells that had been transfected with two gene constructs, 
one containing a STAT5-activated firefly luciferase gene and the other a 
constitutively active Renilla luciferase gene, were stimulated for 6 h with 
wt or mutant GH. The cells were lysed and their firefly and Renilla 
luciferase activities were measured. Normalised (firefly/Renilla) activity 
relative to maximal activity of wt was plotted against GH concentration. 
The activities increase quite linearly so no plateau – and therefore no EC50 
values – could be determined. Instead, the relative activities of the mutants 
were compared to wt at each concentration. Results are presented in figure 
29.  
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Figure 29: STAT5 transcription assay. HEK-293-GHR cells were transfected with a STAT5-
activated Renilla luciferase construct and a constitutively active firefly luciferase construct. The 
cells were stimulated for 6 h with wt or mutant GH after which their Renilla and firefly luciferase 
activities were measured. Total normalised (firefly/Renilla) activity of wt(max) was plotted against 
GH concentration. Data of each graph is from three separate experiments. A. The SN control 
was not able to induce STAT5 activation. ∆188-190 shows lower activation than wt especially at 
1-5 nM but the differences are not significant. B. C189A at 2 nM and C182A at 10 nM show sig-
nificantly lower STAT5 activation than wt GH. C182+9A is similar to wt. Unfortunately the error 
bars are quite high especially at higher concentrations. C. Both R77C and D112G show a some-
what lower STAT5 activation than wt GH but only the difference between wt and R77C at 10 nM 
is significant.  
As can be seen in figure 29A, the supernatant control did not induce acti-
vation of STAT5 pathway. The ∆188-190 mutant seems to be less potent in 
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activating this pathway than wt GH but the difference is not significant. 
C182+9A and wt showed similar STAT5 activation whereas that of C182A 
and C189A was somewhat lower (figure 29B). This difference was signifi-
cant in case of C189A at 2 nM and C182A at 10 nM. Both R77C and D112G 
seemed less efficient in activation of STAT5 pathway than wt but only 
R77C at 10 nM differed significantly from wt (figure 29C).  
∆188-190-monomer and dimer were assayed with rhGH (figure 30). The 
differences seem much more outstanding than in case of the above men-
tioned mutants. Dimeric ∆188-190 was not able to activate the STAT5-
pathway at all and even the monomeric form was far less potent than 
rhGH. Dimer at 5 nM and monomer at 10 nM differed significantly from 
rhGH. 5 nM was the highest concentration of dimer due to low original 
concentration. 
 
Figure 30: STAT5 transcription assay with ∆188-190-monomer and -dimer. HEK-293-GHR cells 
transfected with a STAT5-dependent Renilla luciferase construct and a constitutively active firefly 
luciferase construct were stimulated for 6 h with rhGH and ∆188-190-monomer and -dimer. 
Renilla and firefly luciferase activities of lysed cells were determined. Normalised (Renilla/firefly) 
activity of each sample was divided by maximal rhGH activity and plotted against GH concentra-
tion. ∆188-190-dimer is not able to induce STAT5 activation and the monomer does so to a much 
lower extent than rhGH. Dimer at 5 nM and monomer at 10 nM differ significantly from rhGH. 
The data is from two experiments. 
4.4.3 Antagonistic effect of ∆188-190 
Since it had been hypothesised that the ∆188-190 mutant could be a GHR 
antagonist, its antagonistic effect was also tested in the bioassays. BaF-B03 
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proliferation assay and STAT5 transcription assay were completed as de-
scribed in the previous chapters. B2036, which is Pegvisomant without the 
PEG-residues, is a known GH antagonist and was used as a “positive” 
control in both assays. 0.5 or 1 nM rhGH was used in the transcription as-
say in order to have an as low as possible concentration at which STAT5 
activation was prominent (see figure 30). 0.5 nM rhGH was used in the 
proliferation assay since this concentration had already been established 
for antagonist assays by others in the group. As can be seen in figure 31, 
the antagonist effect of B2036 starts to show at 2:1 and is distinct at 20:1 
molar ratio in STAT5 assay. In BaF-B03 proliferation assay one needs a 50:1 
molar ratio of B2036 in order to slightly reduce proliferation and a 200:1 
ratio is required for a more pronounced effect. We could not achieve such 
ratios with the ∆188-190-monomer and -dimer due to the rather low origi-
nal concentrations. However, since the molar ratio of dimeric vs mono-
meric – assumably wt – GH in patients was 3-5:1, going up to a 10:1 molar 
ratio could have been enough to see if there was any antagonistic effect. 
Only a 5:1 ratio was achieved with ∆188-190-dimer in the proliferation as-
say.  
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Figure 31: Antagonistic effect of ∆188-190. In this graph is combined data from both bioassays, 
where the antagonistic effects of ∆188-190-monomer and -dimer were studied. Continuous lines 
represent results from STAT5 transcription assay and the dashed ones from BaF-B03 proliferation 
assay. 0.5 nM rhGH was used in the proliferation assay and 0.5-1 nM in the transcription assay. 
B/B0 100 is the value obtained with this rhGH only. The known GH antagonist B2036 was func-
tional in STAT5 assay starting from a 2:1 antagonist:rhGH ratio. In BaF-B03 assay a ratio of 50:1 
was required. The dimer was tested up to 5:1 molar ratio in the proliferation assay and 10:1 in the 
transcription assay but in none of them neither an antagonistic nor agonistic effect was seen.  
Monomer was tested up to 10:1 in both assays and it had only an agonistic effect. STAT5 assay 
was repeated three times with the ∆188-190-dimer but otherwise the data is from single experi-
ments.  
The obtained luminescence counts of BaF-B03 assay and normalised 
Renilla/firefly luciferase activity in STAT5 assay were divided by the signal 
obtained without antagonist, hence only rhGH. These B/B0 values were 
plotted against the molar ratio of antagonist and rhGH. Only B2036 dis-
played a clear antagonistic effect in both assays. Biological activity of sam-
ples with ∆188-190-dimer remained unchanged and that of the monomer 
samples increased, as could be expected based on the stimulation assays. 
4.5 Stability 
Two methods were applied for stability studies. Simulating physiological 
conditions, GH was incubated at 37°C in human serum and its concentra-
tion was followed over time. In the second experiment GH was exposed to 
the digestive enzyme trypsin. 
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4.5.1 Half-life in serum 
Concentrations of wt, phGH and mutant GH were observed over 24 h or 
144 h when incubated in low [GH] human serum at 37°C. Samples were 
collected at different time points and their concentrations were measured 
by TR-IFMAs. The resulting concentrations were divided by the ones ob-
tained at t(0). Means of these B/B0 values measured by two different anti-
bodies were plotted against the incubation time. Results can be seen in 
figure 32. 
Concentration of wt was not altered during 24 h, whereas concentrations 
of C182A and C189A dropped rather quickly. Roughly estimated half-lives 
of C182A and C189A were 4 and 15 h, respectively. C182+9A did not have 
a reduced stability compared to wt GH. ∆188-190-monomer was clearly 
less stable than wt GH, but did not drop below 50% during the 24 h incu-
bation. However when it was incubated for 144 h, the concentration 
dropped more quickly and was below 50% as the 24 h sample was taken. 
In addition to ∆188-190-monomer, also ∆188-190-dimer, phGH and mu-
tants R77C and D112G were incubated in serum for 144 h. ∆188-190-
monomer was the only sample with reduced stability compared to wt and 
phGH. ∆188-190-dimer had an increased stability instead. 
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Figure 32: Half-life in serum. Wt, ∆188-190-monomer, C182A, C189A and C182+9A were incu-
bated in low [GH] human serum for 24 h (A) and wt, phGH, ∆188-190-monomer and -dimer, 
R77C and D112G for 144 h (B). During the 24 h incubation, all mutants except for C182+9A 
were less stable than wt GH. During the 144 h incubation, ∆188-190-monomer was less stable 
and ∆188-190-dimer more stable than wt or phGH. R77C and D112G had similar stability as wt 
and phGH. Bars represent the different concentrations measured by two antibodies. 
4.5.2 Trypsin resistance 
Resistance of wt and mutant GH against trypsin digestion was studied by 
incubating the samples with trypsin for 2 h and then observing differences 
in degradation in Western blot. Results are presented in figure 33. 
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Figure 33: Trypsin resistance. Wt and mutant GH were digested with trypsin for 2 h and the deg-
radation was studied by Western blot. Wt GH displayed moderate degradation whereas the mu-
tants C182A and C189A were much more degraded after two hours. ∆188-190-dimer showed 
very high resistance against trypsin whereas the monomer could not even be detected in the 
samples incubated with trypsin (except for the 0 min sample). C182+9A and R77C showed deg-
radation comparable to wt.  
The results from trypsin digestions were similar to the ones from serum 
incubations. Wt, R77C and C182+9A were slightly degraded over the 2 h 
whereas ∆188-190-dimer remained unchanged. C182A and C189A were 
less stable than wt, and ∆188-190-monomer could barely be detected in 
Western blot in reducing conditions, as already noticed in chapter 4.2. 
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5 Discussion 
The main objective of this PhD project was to characterize the novel het-
erozygous GH deletion mutation Δ188-190 found in patients with retarded 
growth. Along the way two subprojects evolved: 1) investigating the role 
of the C-terminal disulfide bridge in human GH, which is disrupted in the 
novel mutant, and 2) further characterizing the previously reported GH 
mutations R77C and D112G, which also have been identified in heterozy-
gous state in patients with short stature. Mainly the same experimental 
methods were applied in all projects. The experimental approach is dis-
cussed first and then the outcome of each project is discussed in its own 
chapter.  
5.1 An array of methods for characterization of recombinant 
GH was established 
Each mutation was induced to the GH-1 gene by site-directed mutagenesis 
after which the cDNA was subcloned into the expression plasmid 
pcDNA3.1. We used the human cell line HEK-293 for expression of wt and 
mutant GH. GH was secreted into the growth medium, which was col-
lected for experiments. Western blot analysis showed whether mutants 
and wt GH were secreted in similar concentrations and their level of 
dimerization or oligomerization. Exact GH concentrations were deter-
mined by TR-IFMAs. The GH-containing supernatants were used as such 
for the experiments except for the separated monomer and dimer. We tried 
at first to purify the GH with 10A7- and 5E1-coupled NHS-activated 
Sepharose 4 Fast Flow resins and beads. With both mAbs the recovery was 
very low, approximately 10%. With large amounts starting material and 
severe concentration afterwards one would gain sufficient amounts to be 
used in the bioassays but since the supernatants turned out to be suitable 
as such, purification was set aside. 
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The mutants were characterized in regard to binding affinity, bioactivity 
and stability. Binding to GHBP was studied by two immunoassays and to 
GHR by a cell assay. Binding affinities obtained by the different methods 
correlated well with each other, and if one does not have the possibility to 
do the cell assay requiring radioactive GH one can quite well rely on the 
results from the immunoassays. Bioactivity was studied by BaF-B03 cell 
proliferation assay and STAT5 transcription assay. These two approaches 
cover different aspects of the bioactivity since one measures signal trans-
duction and the other the growth promoting effect. Cell proliferation was 
studied in the PRL receptor (PRLR)-expressing Nb2 cells as well but the 
method was abandoned due to very low reproducibility. Stability was 
studied by incubation in low GH human serum and by digestion with 
trypsin.   
5.1.1 Secretion 
Studying the secretion of a GH mutant and especially its secretion to-
gether with wt GH is another important aspect when characterizing GH 
mutants. All the mutants included in this thesis were found in patients 
with normal to high GH levels so the secretion did not become a focus of 
this project. However, secretion and co-secretion with wt GH of the mu-
tants P89L, V110F, I179M and R183H, which were characterized by MSc 
Maria Hennig, were studied in the mouse pituitary cell line AtT-20. The 
cells were transfected with either wt GH, wt & mutant GH or mutant GH 
constructs and GH concentrations in supernatant and cell lysates were 
measured. One would get a more accurate look at the synthesis and secre-
tion by immunofluorescence staining of GH and the involved cell organ-
elles, Golgi apparatus and endoplasmatic reticulum, as done by Salemi et 
al. [2005]. In the experiments done in our group it seemed that all the stud-
ied mutants were produced in lower amounts than wt GH and especially 
P89L and V110F even hampered production of wt GH. All in all, the prob-
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lem seemed to be in production and not secretion. On the contrary, when 
Salemi et al. studied P89L and R183H, the problem seemed to be more of 
the secretory kind [Salemi, 2005]. 
5.2 The novel GH mutant Δ188-190 has reduced bioactivity but 
not a high antagonistic potency 
5.2.1 Starting point 
This project arose in the year 2000 when 10-year-old twin girls were diag-
nosed with GH deficiency based on low GH and IGF-1 levels. GH treat-
ment was started but the achieved growth acceleration was only modest. 
The GH-1 gene of the girls was sequenced and a heterozygous deletion of 
amino acids 188-190 was discovered. Amino acid 189 is a cysteine forming 
the C-terminal disulfide bridge of GH and thus such mutation resulted in 
an unpaired cysteine, C182. The first hypothesis [Weigel, 2004] was that a 
secretory problem caused the GHD of these patients since this had been 
observed in patients carrying heterozygous mutations that causes exon 3 
skipping [McGuinnes, 2003]. Skipping of exon 3 deletes C53 and thereby 
leaves C165 unpaired. Disruption of the C-terminal disulfide bridge had 
not been confronted in a patient before. When a closer look was taken on 
the serum GH levels of the patients it turned out that there was no secre-
tory problem after all. By using more sensitive immunoassays employing 
monoclonal antibodies, GH levels above the normal range were measured. 
The GH just could not have been shown in the previous assays since most 
of it was in a dimeric form. Dimer formation was shown by FPLC analysis, 
Western blot and TR-IFMAs employing GH dimer -specific monoclonal 
antibodies. GH dimers and oligomers are also a normal but rather minor 
component of serum GH [Baumann, 1999].   
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5.2.2 GHR antagonist hypothesis 
High GH levels and low IGF-1 levels, the assumption that also wt GH was 
present in circulation and the patients’ unresponsiveness to GH therapy 
suggested that the new GH mutant, ∆188-190, could be a GHR antagonist. 
A similar case had been reported by Takahashi et al. in 1996. A boy had a 
heterozygous R77C mutation and thus also an unpaired cysteine and it 
was suggested that this mutant would form a dimer acting as a GHR an-
tagonist. This hypothesis was proven wrong later on: R77C was found to 
have similar bioactivity as wt GH, and when R77C was combined with wt, 
the effect was fully synergistic and not antagonistic [Petkovic, 2007(x2)]. 
Nonetheless, maybe the new ∆188-190 mutant could be a GHR antagonist. 
Unfortunately, by the time of these findings it was too late to treat the pa-
tients with another approach: a combination of somatostatin analogue and 
recombinant GH. This way the endogenous production of the mutant 
would have been suppressed and the recombinant GH could have acted 
unopposed.  
Even though it was too late to help the patients carrying the novel muta-
tion – at least until they have children of their own – there was another 
group of patients that could benefit from this mutant. Namely, a GHR an-
tagonist can be used in treatment of acromegaly. There is an interest to 
find a new GH antagonist since the only one on the market thus far, Pegvi-
somant, is extremely expensive and doses as high as 10-20 mg/day are re-
quired [Trainer, 2000]. Monthly costs are $2812 on the minimal dose ac-
cording to the National PBM Drug Monograph for Pegvisomant 
[Goodman, 2003]. If the deletion mutant dimer would be an effective an-
tagonist as such, no pegylation due to its high stability would be required. 
Not needing the pegylation would lead to both lower preparation costs 
and lower doses since the PEG residues make up 48-58% of the molecular 
weight of Pegvisomant and pegylation leads to a 20-fold decrease in bind-
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ing affinity to GHR [Pradhananga, 2002]. Of course, this would require 
that the antagonistic effect of the Δ188-190 dimer would be at least as high 
as that of Pegvisomant. 
 
Figure 34: Antagonist design. As depicted in model 2 (picture c), the only known GH antagonist, 
Pegvisomant, binds to GHR by the high-affinity binding site 1 but due to the bulk in binding site 2, 
the second receptor cannot bind optimally. The conformational change required for signal trans-
duction does not take place and simultaneously the receptor is occupied and wt GH cannot bind. 
Model 1 (picture b) describes the antagonist hypothesis from the time when Pegvisomant was 
invented. The figure has been published by Tallet et al. in 2008. 
The action of Pegvisomant is based on a G120K mutation. The mutant 
binds with normal affinity via its high affinity binding site 1 but due to the 
bulkier lysine instead of glycine at binding site 2, the mutant is not able to 
induce the conformational change in the receptor required for signal 
transduction. Mechanism of GH antagonist action is described in figure 34 
[Kopchick, 2002; Tallet, 2008]. Since the Δ188-190 mutation is in the prox-
imity of binding site 1 and since disulfide bonds only stabilize the three-
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dimensional structure without changing it, it is likely that the intermolecu-
lar disulfide bond would be formed between the free cysteines at position 
182, leaving only the low-affinity binding site 2s of a mutant dimer unal-
tered and available for receptor binding. Preferably high-affinity binding 
would be desired from a GH antagonist. 
5.2.3 Experimental approach 
As this project was started, only clinical and sequencing data existed for 
the novel deletion mutant. Serum of the patients had been studied by 
FPLC, Western blot and TR-IFMAs, indicating that their GH was in 
dimeric form. We produced the mutant in vitro and characterized it re-
garding its binding affinity to GHR and GHBP, its bioactivity and stability. 
Antagonistic effect was studied in comparison to B2036, the non-pegylated 
form of Pegvisomant. 
5.2.4 Outcome 
5.2.4.1 Different oligomerization pattern in vitro and in patient serum, 
and variation in stabilities 
Δ188-190 and wt GH were produced in HEK-293 cells. Because of the pa-
tients’ high GH levels, impaired secretion was unexpected and since simi-
lar amounts of mutant and wt GH were measured in cell supernatant, the 
secretion was not further investigated. Based on patient data, Δ188-190 
was expected to form a dimer but this turned out to be only partly true: in 
Western blot of the cell supernatants more dimer was detected in Δ188-190 
than in wt sample but there was also an approximately equal amount of 
monomer. Even some trimer was present in the Δ188-190 sample but none 
in wt. Thus, in vitro, the free cysteine drives the Δ188-190 mutants to form 
covalent disulfide dimers and trimers but monomer is just as abundant, 
whereas in patient serum trimer was absent and monomer was only pre-
sent in small amounts, presumably formed by wt GH. One cause is proba-
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bly the completely different media that the GH is in: cell culture medium 
vs. human serum, in which the presumably less stable forms, mutant 
monomer or trimer, are more prone to breakdown and degradation. The 
dimer was shown to be extremely stable both in serum incubation test and 
when digested with trypsin, whereas monomer was very unstable.  
Another plausible reason for differences in oligomerization is that the 
HEK-293 cell culture does not completely resemble the somatotrophs 
where GH synthesis takes place. For example the oxidative power and 
presence of protein disulfide isomerases in the ER, where the post-
translational modifications take place, could vary between different cell 
types. In addition, we cannot be sure that the dimer found in patients is a 
mutant homodimer. Even though it would be energetically favourable to 
form disulfide bonds between two mutant molecules with free cysteines, 
the in vivo synthesis may lead to formation of a wt/mutant heterodimer or 
a mixture of all possible homo- and heterodimers. However, the resulting 
free cysteines would be highly reactive and probably be oxidatively modi-
fied, for example by cysteinylation which is common for many plasma 
proteins [Ghezzi, 2005].  
5.2.4.2 Separation of monomer and dimer 
In order to study the binding affinity and biological effects of exclusively 
the mutant homodimer, dimer and monomer in cell supernatant of the 
Δ188-190 producing cell line were separated by size-exclusion chromatog-
raphy. The separation was confirmed in Western blot. In reducing condi-
tions the monomeric mutant could barely be detected even though the 
non-separated Δ188-190 mutant in cell supernatant was detected without 
problems. This is probably due to partial degradation during the process 
of production, storage and purification, which differs quite a lot from that 
of the Δ188-190 produced by transient transfection. First of all, during the 
production in cell line the medium of the MiniPERM culture was un-
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changed for 10 days, after which it was stored at 4°C until chromatogra-
phy, whereas the transient transfection only required a few days in cell 
culture conditions, after which the supernatant was stored in -20°C and 
was ready for analysis as such. Also the chromatography is a harsh proc-
ess for an unstable molecule like the Δ188-190 monomer.   
Since the production of monomeric and dimeric ∆188-190 mutant required 
vast amounts of starting material and was a rather slow process, one had 
to be careful deciding which experiments to do with them. Testing the an-
tagonistic effect was our main goal and therefore the focus was on bioas-
says. 
5.2.4.3 Reduced binding affinity to GHR and GHBP 
Binding affinity was studied by immunoassays employing GHBP, i.e. the 
extracellular domain of GHR, and an experiment where the GH would 
bind to full-length GHR on HEK-293 cell surface. Unlike expected from an 
antagonist, the mutant displays lower binding affinity than wt GH. In the 
immunofunctional assay testing the integrity of both GH binding sites 
only 4% of total Δ188-190 could be measured. In competitive GHBP bind-
ing assay the mutant had a significantly lower binding affinity compared 
to wt GH: approximately 2.8x more mutant was required for same effect 
(IC50). When binding to GHR, 2.5x more mutant was needed for same ef-
fect. These assays were not done with the separated monomer and dimer, 
except for the first step of competitive GHBP assay where concentration at 
10% maximal binding was determined. However, the 10% of maximum 
could not be reached with the dimer at all. Approximately 2.5x the amount 
of wt was needed to achieve the same binding with monomer, and theo-
retically, one would need 200x the amount of wt to achieve the same bind-
ing with the dimer. Thus the binding affinity of the Δ188-190 mutant – es-
pecially in its homodimeric form – does not speak for the antagonist 
hypothesis. 
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5.2.4.4 Reduced ability to activate the Jak/STAT pathway and to 
induce cell proliferation 
Δ188-190 in cell supernatant is biologically less active than wt GH. In BaF-
B03 cell proliferation assay the EC50 of mutant is approximately twice as 
high as that of wt. Mutant-induced activation of STAT5 dependent tran-
scription was lower than wt-induced activation at each concentration. Both 
assays were also done with the separated monomer and dimer, both of 
which were even less bioactive than the mutant in cell supernatant. The 
dimer was not able to induce STAT5 dependent transcription at all. How-
ever in the proliferation assay it was active at high concentrations. One 
possibility is that the dimer is broken and the effect is in fact induced by 
monomer but results from stability tests do not support this - if a 7-day 
incubation in human serum does not break the dimer, a 24 h incubation in 
cell culture is unlikely to do it. 
The results obtained with separated monomer and dimer do not correlate 
with the results obtained with the mutant-containing cell supernatant. 
Based on Western blot, the supernatant contains approximately equal 
amounts of dimer and monomer and therefore one would expect that its 
binding affinity and biological activity would be close to the mean of those 
of monomer and dimer. Instead, the binding affinity of Δ188-190 in super-
natant resembles that of monomer and in the bioassays monomer is even 
less bioactive than the supernatant sample. This is not due to the use of wt 
GH and rhGH because they have similar activities in both the proliferation 
assay and the transcription assay. As already mentioned the monomer 
cannot be recognized in Western blot and is probably partly degraded 
during the lengthy production. This could also lead to the rather low bio-
activity and binding affinity of the monomer but cannot explain the rela-
tively high bioactivity and binding affinity of the Δ188-190 supernatant. 
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5.2.4.5 Inhibition of wt action 
A 10-20 mg daily dose of Pegvisomant results in 10,000-100,000 ng/ml se-
rum concentration. GH levels in acromegalic patients are usually around 
10 ng/ml [Trainer, 2000], and thus a 1,000-10,000:1 Pegvisomant:serum GH 
mass-to-mass ratio is needed in order to adequately reduce serum IGF-1 
levels of the patients. Since the PEG5000 residues make up approximately 
half of the mass of Pegvisomant and since the non-pegylated form of Peg-
visomant, B2036, has a 30-40-fold higher affinity to GHR [Ross, 2001], one 
could estimate that a 10-200:1 B2036:GH ratio suffices for an antagonistic 
effect. B2036 turned out to be effective already at a 2:1 antagonist:rhGH 
ratio in the STAT5 transcription assay and at 50:1 in the proliferation assay. 
The latter proportion would maybe have been lower if a lower concentra-
tion of rhGH would have been applied. With B2036 this was not a problem 
since high concentrations were available but by applying a lower rhGH 
concentration, a higher Δ188-190:rhGH proportion could have been 
achieved.  
Inhibition was studied with the separated Δ188-190 monomer and dimer. 
Monomer had only an agonistic effect whereas dimer had no effect at all. 
Monomer was tested up to 10:1 ratio in both assays and dimer up to 10:1 
in STAT5 assay and 5:1 in BaF-B03 assay. One has to keep in mind that the 
molar ratio of dimer is just half the mass-to-mass ratio. In the patients the 
molar dimer to monomer ratio was 3-5:1. Hence we expected that the pos-
sible antagonistic effect of the Δ188-190 dimer would be prominent at a 
lower mutant:wt ratio than that of Pegvisomant or B2036. Unfortunately in 
the proportions that we studied no antagonistic effect of the dimeric Δ188-
190 mutant could be observed.  
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5.2.5 Conclusions 
Even though the binding affinity of the Δ188-190 mutant is low and it does 
not seem to inhibit the action of wt GH in vitro, it cannot be ruled out that 
it would be an antagonist. Since the dimer is extremely stable, it is the 
most abundant GH isoform in the circulation. Even with its reduced bind-
ing affinity, it confronts a GHR much more often than the monomer and 
thus could interfere with binding of the monomer or rhGH given as ther-
apy. But even if the dimer has an antagonistic effect, it cannot be a very 
potent antagonist: the patients were not completely unresponsive to GH 
therapy and the low binding affinity to GHR will be a problem when a 
high-potent antagonist is being developed.  
 
Figure 35: GHR can be activated by a GH dimer. In figure A is the common model of single GH 
molecule binding two GHBP molecules. In figure B is a dimer of the GHR antagonist G120R 
bound to two GHBP molecules. According to Yang et al., this dimer is able to activate the recep-
tor even though its monomeric form is not. The figure was published by Yang et al. in 2008. 
Yang et al. [2008] studied two artificial GH dimers. The wt-wt dimer had 
all four binding sites available and the G120R-G120R had only two bind-
ing site 1s since the binding site 2s were located in the interface. G120R-
G120R bound by two GHBP molecules is presented in figure 35. The mu-
tant G120R is the GHR antagonist that lead to development of Pegviso-
mant, where the mutation was changed to G120K [Chen, 1990; Kopchick, 
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2002]. It was shown that both a wt-wt dimer and a G120R-G120R dimer 
were able to activate GHR. This suggests that the GHR dimer is much 
more flexible than generally believed. Therefore, the Δ188-190 dimer 
should not be too large for GHR binding either. However as already men-
tioned, since the mutation is adjacent to binding site 1, the dimer is proba-
bly built in such way that binding site 1 becomes hidden and the dimer 
has two low affinity binding site 2s exposed. From this point of view the 
low binding affinity is expected.  
Our momentary hypothesis is that the reason for the retarded growth in 
patients carrying the heterozygous Δ188-190 mutation is that the mutant 
forms a dimer which is able to hamper action of wt GH. Very high stability 
of the dimer leads to its accumulation and therefore, despite of low recep-
tor binding affinity, it has the quantitative advantage against the wt GH. 
However, due to some contradictory data, final conclusions cannot be 
made yet. For example, it cannot be ruled out that the GH dimer found in 
the patients would be a wt/Δ188-190 heterodimer or a mixture of hetero- 
and homodimers. This will be further discussed in chapter 6.2. 
5.3 The C-terminal disulfide bridge is crucial for full 
functionality of GH binding site I 
5.3.1 Starting point 
An important feature of the novel Δ188-190 mutation was that it caused 
disruption of the extremely conserved (see table 1) C-terminal disulfide 
bridge of GH between C182 and C189. Its role has been investigated only 
scarcely and mostly decades ago. Based on experiments with bovine GH, 
this disulfide bridge has been claimed to be unimportant for secretion, 
receptor binding and growth promoting effect [Chen, 1992]. However its 
conservation and location within GH binding site 1 [Cunningham, 1989 & 
1991] speak for its importance. The disulfide bridge between C53 and C165 
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has been more under interest than the C-terminal one, partly because it is 
disrupted in patients with a heterozygous Δ32-71 mutation (Δexon3), hav-
ing a dominant negative effect. In addition a homozygous C53S mutation 
has been identified in a boy with retarded growth. Unlike the Δ32-71 mu-
tation, this one did not show a dominant negative effect [Besson, 2005].  
Cunningham et al. [1989, 1991] performed several alanine mutations in 
order to find out which amino acids are important for receptor interaction. 
They showed that the cysteine C182 is involved in binding site 1 and that 
the mutant C182A displays reduced receptor binding. They could not ana-
lyse mutant C189A because of its low expression in E. coli [Cunningham, 
1989]. In order to gain more information about the role of the C-terminal 
disulfide bridge, we converted one or both of the participating cysteines to 
alanines, creating mutants C182A, C189A and the double mutant 
C182+9A. These mutants were characterized similarly as Δ188-190.  
5.3.2 Outcome 
5.3.2.1 Normal secretion but low stability caused by an unpaired 
cysteine 
In the beginning only mutants C182A and C189A were constructed and 
produced. In our HEK-293 cells even C189A was secreted in similar 
amounts as wt GH. A special feature of C182A and C189A was very low 
stability in comparison to wt GH. This made us speculate that the free cys-
teine and not the structural role played by the disulfide bridge could be 
responsible for the rapid degradation, both when incubated in human se-
rum and digested with trypsin. In order to investigate this, a third mutant, 
where both involved cysteines were converted to alanines, C182+9A, was 
constructed and characterized. It turned out that, in fact, the stability was 
recovered by removing the free cysteine. Thus the disulfide bridge only 
contributes to stability of the molecule by keeping the reactive cysteines 
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from reacting with other surrounding molecules. It is actually all in all 
more accurate to investigate the role of a disulfide bridge by removing 
both involved cysteines. Betz [1993] studied the meaning of disulfide 
bonds for protein stability in general but concluded that it is hard if not 
impossible to study their role by removing or mutating a cysteine since 
one cannot maintain the exact polarity and volume of the disulfide state. 
In addition, the unpaired cysteine of a protein-S-H can be oxidised form-
ing a protein-S-X, X being an available molecule in the expression system, 
such as glutathione or free cysteine [Ghezzi, 2005]. 
5.3.2.2 Integrity of the C-terminal disulfide bridge critical for binding 
affinity to GHR and GHBP 
As demonstrated in figure 36A, the amino acids of the C-terminal disul-
fide bridge of GH are within binding site 1 in direct contact to the extracel-
lular domain of GHR (GHBP). Therefore it was expected that it has a high 
importance for binding affinity. All the mutants with disrupted C-terminal 
disulfide bridge had a significantly reduced binding affinity to GHBP and 
to full-length GHR and it did not make a difference whether a free cys-
teine was present (binding to full-length GHR was not analysed with 
C182+9A). Consequently, it is probable that the free cysteines did not react 
with any large molecules or perhaps the cell culture conditions were not 
very oxidative and the cysteines remained in the thiol (protein-S-H) state.  
C189A was the disulfide bridge mutant with lowest binding affinity in all 
binding experiments, thus a free cysteine at position 182 or the alanine at 
189 hampers the binding more than vice versa. Conservation of the disul-
fide bridge in GH family members and also in different species (see table 
1) is probably due to its location within the binding site. In figure 36B the 
GH family member prolactin is bound to the ECD of its receptor and even 
though the second cysteine (C199) cannot be seen, it is apparent that the 
disulfide bridge is in close contact to the receptor. 
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Figure 36: The C-terminal disulfide bridge is located within binding site 1. A. A pink GH molecule is 
bound to a light green GHR ECD (i.e. a GHBP). C182 and C189 of GH are yellow and both are in 
contact with the receptor. B. A light blue PRL molecule is bound to a violet PRLR ECD. C-
terminal disulfide bridge of PRL is formed between C191 (yellow) and C199 but the latter is not 
included in the 3D model. The last amino acid included is N198, which is coloured magenta. GH-
GHBP model is by Clackson et al. [1998] and PRL-PRLR ECD model by Svensson et al. [2008]. 
5.3.2.3 Bioactivity close to wt despite of lower binding affinity 
In addition to the lowest binding affinity, C189A turned out to have the 
lowest bioactivity of these mutants. Even though C182A and C182+9A had 
a reduced binding affinity as well, their bioactivity was similar to wt GH, 
except for C182A at the highest concentration in STAT5 assay. C189A on 
the other hand displayed a lower bioactivity than wt in both BaF-B03 pro-
liferation assay and STAT5 assay. C189A is structurally more similar to 
Δ188-190 than C182A or C182+9A, and – based on our data – also func-
tionally. 
5.3.3 Conclusions 
C182A and C189A had very low stability in comparison to wt GH. Study-
ing the mutant C182+9A, which does not have the C-terminal disulfide 
bridge but does not have a free cysteine either, revealed that the reduced 
stability had been caused by the free cysteine of C182A and C189A and not 
by the absence of the disulfide bridge per se. However, as was seen in case 
of R77C (discussed in chapter 5.4), stability of a GH molecule is not always 
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reduced if a free cysteine is present. This could be due to the different lo-
cations of the free cysteines even though all the studied mutants with a 
free cysteine, i.e. Δ188-190, C182A, C189A and R77C, dimerize more than 
the ones with a paired number of cysteines, suggesting that even the free 
cysteine of R77C is exposed and reactive. Evolutionally the contribution of 
the C-terminal disulfide bridge to stability may still be important since the 
deletion of one cysteine is more likely to happen than removal of both of 
them. In addition, reduced binding to GHBP reduces the stability even 
more due to loss of the protective effect of GHBP. 
The importance of the C-terminal disulfide bridge for binding affinity did 
not come as a surprise because of its location within GH binding site 1. 
Despite of this, the mutants were able to induce signal transduction and 
cell proliferation almost as wt GH, only bioactivity of C189A was some-
what lower. It is not unusual that binding affinity does not correlate with 
bioactivity [Haugh, 2004]. Figure 37 describes a kinetic model, where all 
the different destinations of a GH-GHR complex are taken into account. 
Unfortunately this model was created before the current idea of a pre-
existing receptor dimer was more widely accepted. However, the most 
important point is that receptor binding is an extremely dynamic process 
and one has to take into account at least GHR synthesis, internalization of 
the GH-GHR complex and its recycling and degradation.  
According to Haugh [2004], an internalized 1:2 GH-GHR complex can 
only be degraded but a 1:1 complex can also be recycled. It would be in-
teresting to know what would happen with a 1:2 complex if the GH was a 
mutant with low binding affinity and reduced ability to initiate signal 
transduction. If this would turn on the recycling system, we would have 
an explanation for the normal bioactivity despite of poor binding affinity. 
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Figure 37: Illustration of GH receptor binding and trafficking by a kinetic model [Haugh, 2004]. Unfor-
tunately the model is not completely accurate because of the outdated pattern of receptor bind-
ing but it gives an idea of the complexity of the process. L is an extracellular ligand, black and 
white circles representing GH binding site 1and 2, respectively. R is a free GHR, C is a 1:1 GH-
GHR complex (inaccurate) and D is a 1:2 GH-GHR complex. 
5.4 GH mutants R77C & D112G present in patients with short 
stature barely differ from wt GH in vitro 
5.4.1 Starting point 
Both R77C and D112G were first identified by Takahashi et al. [1996 & 
1997]. R77C drew some attention in the medical circles since it was 
claimed to form a dimer with an antagonistic effect [Chihara, 1998; Taka-
hashi, 1996]. Ten years later, however, the same mutation was found in 
another family by Petkovic et al. [2007(x2)], and they showed that R77C 
did not have any antagonistic potency. Since we were studying a possible 
antagonist as well, it was interesting to take this mutant along to our stud-
ies. D112G was included since no new data about it had been published 
since the first publication by Takahashi et al. in 1997, where it was shown 
to have a reduced binding affinity and bioactivity. In fact, all the missense 
mutants shown in figure 12 were cloned and studied to some extent, ex-
cept for the recently published D116E [Dateki, 2009]. Results from the 
characterization of P89L, V110F, I179M and R183H can be found in the 
Master’s thesis of Maria Hennig [2010].   
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5.4.2 Slight reduction in bioactivity the only difference to wt GH 
Both R77C and D112G behaved very similarly as wt in all our experi-
ments, except for the STAT5 transcription assay, where both had a slightly 
reduced activity in comparison to wt GH. Binding affinity of R77C was 
only tested to GHBP but since in all other cases the two binding affinities 
correlated perfectly, we assume that R77C does not have a reduced bind-
ing affinity to GHR either. R77 was not included in Cunningham’s epitope 
mapping since it was not part of an epitope that was believed to take part 
in receptor binding. D112A was reported to have the same receptor dimer-
izing activity as wt GH [Cunningham, 1989 & 1991]. On the GHBP-GH-
GHBP 3D model (see picture 38) it seems that R77 indeed is far from both 
binding sites but D112 is quite close to binding site 2.  
 
Figure 38: Affect of mutations R77C and D112G on GH-GHBP interaction. On this model of a 1:2 
GH:GHBP complex [Sundström, 1996] one can see that the R77C (orange) mutation is unlikely 
to affect receptor binding. D112 (cyan) is rather close to binding site 2 but since it is substituted 
with a tiny glycine, it is improbable to hamper binding either. Amino acids’ structures are from 
PDB. Arginine, cysteine and aspartic acid are hydrophilic and glycine is amphipathic, thus the po-
larities do not cause problems either. Structures of all amino acids can be found in appendix I. 
In the patient D112 is substituted with a glycine which is much smaller 
than the original aspartic acid and therefore is not likely to interfere with 
site 2 binding. None of the substitutions, R77C or D112G, change polarities 
either and thus would not be expected to affect protein folding. Takahashi 
et al. [1997] showed that D112G tended to form a 1:1 complex with GHBP 
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rather than 1:2 complex formed by wt GH. Yet, the fact that D112G had a 
very similar IC50 as wt GH in binding to the full-length GHR indicates an 
unaltered binding affinity.  
As already mentioned in chapter 5.3.3, the free cysteine in R77C causes it 
to dimerize somewhat more than wt but does not seem to affect any other 
properties of the molecule. It is surprising that a free cysteine at C-
terminus remarkably reduces the molecule’s stability as seen in case of 
C182A and C189A, but the C77 on helix 2 has no consequence in this re-
gard. An explanation could be that the C77 is deeper embedded within the 
protein and therefore less reactive than the C-terminal cysteines.  
5.4.3 Conclusions 
Our results were not consistent with the ones published by Takahashi et 
al. [Chihara, 1998; Takahashi, 1996 & 1997]. Data concerning R77C was 
already disproved by Petkovic et al. [2007(x2)] and our results are very 
similar to theirs – R77C resembles wt GH both in receptor binding and 
bioactivity although in our STAT5 assay the bioactivity was somewhat re-
duced. The explanation offered by Petkovic et al. is that the mutant acti-
vates GHR/GHBP transcription less than wt GH and therefore also an ef-
fect on somatic growth could be seen. This approach was not included in 
our studies. We would still like to speculate that the slight reduction in 
bioactivity could play a role in the patients. It is known that one functional 
allele of the GH-1 gene is sufficient for normal growth, as found in het-
erozygous relatives of type IA IGHD patients [Binder, 2002; Mullis, 2005 & 
2007]. Homozygosity on the other hand leads to severely retarded growth. 
Situation of a patient with heterozygous expression of bioinactive GH is 
quite different from the heterozygous deletion. The GH mutant with re-
duced bioactivity still occupies the receptor and only half of the GH in cir-
culation is fully active.  
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In case of R77C, relatives also carrying the mutation did not have retarded 
growth. Height of the Japanese boy was -6.1 SD at the age of 5 years but 
that of his father, who also carried the mutation, was only -0.2 SD. How-
ever, presence of the mutant could not be detected by isoelectric focusing 
in the father’s serum. Approximately twice as much wt GH as mutant was 
found in the boy. Genomic imprinting could explain the different expres-
sion patterns but was not further investigated [Chihara, 1998; Takahashi, 
1996]. The Syrian boy with the same mutation had a height of -2.5 SD at 
the age of 6 but finally reached -1.9 SD without GH therapy. The boy’s 
mother, aunt and grandfather, who also carried the mutation, had heights 
of -1.4, -1.3 and -1.7 SD, whereas heights of non-affected family members 
were -0.8 to -1.5 SD. Mutant was present in similar concentration as wt GH 
in the boy and the mother, as measured by isoelectric focusing [Petkovic, 
2007(x2)]. 
D112G was only found in one girl, in almost four times higher amount 
than wt GH. Her height was -3.6 SD at the age of three but a notable im-
provement was achieved with GH therapy. According to Takahashi et al. 
[1997] the mutant was biologically inactive and had reduced ability to 
form a 1:2 complex with GHBP. All we found was a slight reduction in 
ability to induce Jak/STAT signalling but, as mentioned above, maybe such 
a reduction is enough to cause the phenotype in a patient. The much 
higher concentration of mutant in comparison to wt in the patient could 
not be explained by different stabilities and Takahashi et al. [1997] did not 
have an explanation for this either. It is however questionable if isoelectric 
focusing of one serum sample is enough to draw conclusions of an overall 
expression pattern. 
The poor correlation of patient phenotypes and in vitro results are not ex-
plicable by alterations in genes involved in the downstream effects of GH. 
For instance, the several involved transcription factors are not GH specific 
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and thus impairment on that level would result in a more complex and 
severe phenotype. Defects in IGF-1, unlike GH, would lead to severe pre-
natal growth retardation [Mullis, 2005].  
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6 Outlook 
6.1 Future application of the established methods 
We now have established an array of methods for a fairly rapid characteri-
zation of a GH mutant or for instance a GH variant. There are some pitfalls 
that are important to keep in mind when applying the methods. 
Determination of concentration is an extremely important step and mis-
takes can distort all results. All experiments are based on dose-response 
effects and thus an inaccurate concentration directly leads to a false out-
come. GHBP binding assay is an exception since a concentration with a 
signal corresponding to that of wt is determined. We tried to find the most 
suitable monoclonal antibodies for the TR-IFMAs by taking their binding 
epitopes into account and finally through trial and error. One can predict 
quite well from the location of the mutation which antibodies not to use. A 
more accurate way to determine protein concentration is by measuring the 
OD. However, even after purification by affinity chromatography the 
sample contained at least light and heavy chains of the used antibody, 
which would interfere with the measurement.  
Choice of standard is important for determination of concentration. Tradi-
tionally the phGH preparation 80/505 has been thought to best resemble 
the real situation – a mixture of isoforms and oligomers. However the cur-
rent reference standard is the synthetic 88/624 because of its high purity 
and reproducibility [Jansson, 1997]. We used the phGH 80/505 always 
when determining concentration by TR-IFMAs and 88/624 for the im-
munofunctional assay and for cell experiments with Δ188-190 monomer 
and dimer. The different concentration of wt GH in TR-IFMA and im-
munofunctional assay is probably due to the different standards. 
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The experiments of this project were done over more than a two years time 
and it turned out that variation can be great between assays, especially if 
they were done with long intervals between experiments. It became crucial 
that a mutant was always compared to wt that was analysed in the same 
assay. The two GHBP binding assays for C182 and C189A, done with dif-
ferent stocks of unlabelled GHBP (see fig. 25), are a good example of varia-
tion between assays. Similarly, different stocks of GHBP-b caused the 
maximal signal to vary from 968,000 to 1,640,000 counts (see fig. 24). 
One has to keep in mind that in vitro characterization of a human GH mu-
tant is only an initial step in analysing its mechanism of action. The path 
starting from the production of the mutants in non-somatotrophs to their 
characterization in closed systems is full of divergences from the human 
system. And as was seen in the case of R77C, even the human system can 
react in various ways to the same mutation.  
6.2 Ruling out wt/Δ188-190 heterodimer 
There are still some open questions regarding the Δ188-190 GH mutant. It 
would be important to verify that the dimer found in patients is actually a 
mutant/mutant homodimer as hypothesised and not a wt/mutant het-
erodimer or a mixture of the two. This could be done by mass spectrome-
try (MS), based on the different trypsin digestion patterns of wt and Δ188-
190 mutant. First it has to be made sure that the three amino acid differ-
ence in the C-terminal fragment seen in figure 35 actually can be seen in 
the spectrum. Kohler et al. [2009] have successfully identified different 
growth hormone isoforms by a similar method but the 0.27 kD difference 
of our molecules is rather small in comparison to the 2 kD difference be-
tween 20 and 22 kD GH, for instance. Even if the difference can be de-
tected, we do not unfortunately have enough patient serum in order to 
analyse the dimer of the patients. We would have to settle for analysing 
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the dimer formed after co-transfection with wt and Δ188-190 constructs. 
The rat somatotroph cell line GH3 would optimally be used for this pur-
pose but their challenging cultivation and rather low yield might be a 
problem. The mouse pituitary cell line AtT-20 would probably be the sec-
ond best choice. Dimerization or oligomerization of GH in different cell 
lines was not studied during the PhD project but would be something 
worth taking a look at – preferably before large-scale co-transfections. 
 
Figure 39: Trypsin digestion map of hGH (including signal sequence). Amino acids 188-190 are col-
oured red. The percentage after each trypsin cleavage site is the probability of trypsin digestion. 
The map was created with PeptideCutter, a service provided by SwissProt.  
Prior to analysis, the background has to be reduced and therefore the GH 
has to be purified using mAb 10A7-coupled beads, despite of the unsatis-
factory yield (see chapter 5.1). The result is separated on SDS-PAGE and 
the gel is stained by a MS-compatible staining method, such as Coomassie 
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staining. The desired band is then cut out, trypsinised and analysed by 
matrix assisted laser desorption ionisation-time of flight (MALDI-TOF) 
MS. Dr. Katharina Janek from the Institute of Biochemistry at Charité Uni-
versitätsmedizin has kindly promised to do the analysis after that our pro-
tein is visible on the gel. First wt and Δ188-190 will be analysed in parallel 
and, if a difference in the spectrums can be seen, the dimer band from a 
co-transfection will be analysed. If the mutant clearly predominates, we 
can assume that formation of a mutant homodimer is preferred over a 
wt/Δ188-190 heterodimer.  
6.3 In vivo experiments 
An in vitro characterization can only give directional data about the inves-
tigated molecule. The subsequent step would be to study the mutants in 
an animal model. We are collaborating with Professor John Kopchick at 
Ohio University in order to create a mouse model expressing the Δ188-190 
mutant. He played an important role in development of Pegvisomant and 
has ample experience in GH mouse models [Chen, 1990; Kopchick, 2003]. 
All he needs from us are plasmid constructs containing the wt and mu-
tated GH-1 gene, which then will be subcloned into a suitable vector for 
microinjection into male pronuclei of fertilized C57BL56/SJL mouse eggs 
[Chen, 1990; McGrane, 1988]. Once positive transgenic mice expressing 
either wt or mutant hGH are born, their growth will be observed.  
Another approach for in vivo studies is to inject the mutant into hypophy-
sectomised rats as done in recent studies concerning a GH ligand-receptor 
fusion molecule [Ferrandis, 2010; Wilkinson, 2007]. A large amount of the 
Δ188-190 mutant will be needed and is currently being produced using the 
stably transfected HEK-293 cell line. Dimer will again be separated from 
monomer as described in chapter 3.3.2. It is questionable if the resulting 
dimer is pure enough for the experiment as such. Wilkinson et al. purified 
the examined fusion protein by affinity purification employing a mono-
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clonal anti-GH antibody, similarly as we tried to purify the mutants (see 
chapter 5.1). 
6.4 Looking for antagonists 
Since the GH mutant Δ188-190 did not appear to be a very potent antago-
nist, we started the construction of a series of cysteine mutants, hoping 
that they would form covalent dimers with antagonistic potential. Yang et 
al. showed that both a wt-wt and a G120R-G120R dimer (see fig. 35) were 
able to induce signal transduction, albeit to a lesser extent than wt mono-
mer [Yang, 2008]. This encourages the idea that a GH dimer actually can 
bind to a dimerized GHR. We will only need to find the optimal disulfide 
bridge location for maximal binding not leading to signal transduction. 
Suitable locations for mutations were estimated by in silico modelling us-
ing RasMol.  
6.5 Epilogue 
If new GH-1 mutations related to short stature are to be identified, their 
mechanism of action can at least roughly be determined by the array of 
experiments that we established. Fast characterization could help to treat 
the patients, especially if they do not respond to GH therapy. 
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Appendices 
I. Amino acids [Voet, 2004] 
 Amino acid Abbr. Structure formula 
nonpolar 
Glycine G/Gly NH2-CH2-COOH 
Alanine A/Ala H3C-CH(NH2)-COOH 
Isoleucine I/Ile H3C-CH2-CH(CH3)-CH(NH2)-COOH 
Leucine L/Leu (H3C)2-CH-CH2-CH(NH2)-COOH 
Methionine M/Met H3C-S-(CH2)2-CH(NH2)-COOH 
Phenylalanine F/Phe Ph-CH2-CH(NH2)-COOH 
Proline P/Pro 
NH-(CH2)3-CH-COOH 
|_________| 
Tryptophan W/Trp 
Ph-NH-CH=C-CH2-CH(NH2)-COOH 
|__________| 
Valine V/Val (H3C)2-CH-CH(NH2)-COOH 
polar 
uncharged 
Asparagine N/Asn H2N-CO-CH2-CH(NH2)-COOH 
Cysteine C/Cys HS-CH2-CH(NH2)-COOH 
Glutamine Q/Gln H2N-CO-(CH2)2-CH(NH2)-COOH 
Serine S/Ser HO-CH2-CH(NH2)-COOH 
Threonine T/Thr H3C-CH(OH)-CH(NH2)-COOH 
Tyrosine Y/Tyr HO-Ph-CH2-CH(NH2)-COOH 
polar 
charged 
Arginine R/Arg HN=(NH2)-NH-(CH2)3-CH(NH2)-COOH 
Aspartic acid D/Asp HOOC-CH2-CH(NH2)-COOH 
Glutamic acid E/Glu HOOC-(CH2)2-CH(NH2)-COOH 
Histidine H/His 
NH-CH=N-CH=C-CH2-CH(NH2)-COOH 
|_____________| 
Lysine K/Lys H2N-(CH2)4-CH(NH2)-COOH 
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II. Genetic code [Voet, 2004] 
First 
position 
(5’ end) 
Second position 
Third 
position 
(3’ end) 
 U C A G  
U 
Phe 
Ser 
Tyr Cys 
U 
C 
Leu 
STOP 
STOP A 
Trp G 
C Pro 
His 
Arg 
U 
C 
Gln 
A 
G 
A 
Ile 
Thr 
Asn Ser 
U 
C 
Lys Arg 
A 
Met G 
G Val Ala 
Asp 
Gly 
U 
C 
Glu 
A 
G 
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III. Suppliers of chemicals and reagents, laboratory equipment, kits, con-
sumables and software 
Chemical, reagent Supplier 
100 bp DNA ladder Invitrogen 
1 kb DNA ladder Invitrogen 
125I-hGH MP Biomedicals 
Acrylamide/Bis Solution, 30% Biorad 
Agarose Sigma 
Amersham ECL™ Western Blotting Detection Reagents GE Healthcare 
Amersham Hyperfilm GE Healthcare 
Ampicillin Invitrogen 
APS Biorad 
Biowhittaker® Pro293a-CDM medium Lonza 
Boric acid Sigma 
Bovine γ-globulin Sigma 
Bromophenol blue Sigma 
BSA Sigma 
CaCl2 Sigma 
CYBR® Safe DNA gel stain Invitrogen 
ddH2O VWR 
Dexamethasone Sigma 
DMEM Invitrogen 
DMEM:F12, 1:1 Invitrogen 
dNTP mix Invitrogen 
DTPA Sigma 
EDTA, 0.5 M Sigma 
EtOH Merck 
FCS Thermo Scientific 
Geneticin (G418) Invitrogen 
Gentamicin, 1 mg/ml Sigma 
Glucose Sigma 
Glycerol Sigma 
Glycine Merck 
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HAc Merck 
HCl, 25% Merck 
HEPES Invitrogen 
HRP-labelled α-mouse antibody GE Healthcare 
HS Invitrogen 
Isopropanol ultra for molecular biology Sigma 
Kaleidoscope Prestained Protein Standard Biorad 
KCl Sigma 
KH2PO4 Sigma 
KHP Sigma 
Lane Marker Sample Buffer Thermo Scientific 
LB Agar tablets Sigma 
LB Broth tablets Sigma 
L-glutamine, 200 mM Invitrogen 
Lipofectamine™ 2000 Invitrogen 
Low DNA Mass™ Ladder Invitrogen 
MeOH Merck 
Na2HPO4 Sigma 
Na2HPO4x12H2O Sigma 
NaN3 Sigma 
NaCl Merck 
NaOH, 2 M Merck 
Opti-MEM® Reduced Serum Medium  Invitrogen 
PBS tablets Invitrogen 
Penicillin-Streptomycin, 10,000 U/ml; 10,000 µg/ml Invitrogen 
Pfu DNA polymerase, 0.3 U/µl Promega 
Pfu reaction buffer, 10x Promega 
phGH, IRP 80/505 NIBSC 
Primers Invitrogen 
Pyruvate, 100 mM Invitrogen 
Restriction enzymes, 10 units/µl, and corresponding 
REact® buffers 
Invitrogen 
rhGH, IRP 88/624 NIBSC 
RPMI-1640 Invitrogen 
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Salmon sperm Invitrogen 
SDS Biorad 
Sheep serum Sigma 
Skim milk Merck, Sigma 
Streptavidin-Eu PerkinElmer 
Sucrose Sigma 
TEMED Biorad 
Thenoyltrifluoroacetone Sigma 
Tri-n-octylphosphinoxide Merck 
Triton® X-100 Sigma 
Trizma® base Sigma 
Trypan blue stain, 0.4% Invitrogen 
Trypsin, 100x (for cell culture) Invitrogen 
Trypsin (for analysis) Sigma 
Tween 20, 40 Sigma 
 
Kit Supplier 
DLR™ Assay System  Promega 
HiSpeed MIDI Kit Qiagen 
pcDNA™3.1 Directional TOPO® Expression Kit Invitrogen 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
ViaLight® Plus Kit Lonza 
 
Equipment Supplier 
Autoclave Technomara 
CO2 cell culture incubator Sanyo 
Columbus 12 Channel Head 96 well Strip plate Washer Tecan 
Curix 60 tabletop processor AGFA 
DELFIA® Plate Shaker PerkinElmer 
Eclipse TS100 microscope Nikon 
FPLC Amersham 
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ImageScanner Amersham 
Mastercycler Personal Eppendorf 
Mithras LB 940 Luminometer Berthold Technologies 
Neubauer counting chamber  VWR 
Orbital Shaker Incubator TEQ 
Rocky Rocking platform Biometra 
Thermomixer 5436 Eppendorf 
Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell Biorad 
Typhoon 8600 Variable Mode Imager Amersham 
VICTOR3™ Multilabel Counter PerkinElmer 
 
Consumable Supplier 
96-well flat bottom cell culture plate, white Nunc 
96-well flat bottom microtiter plate, clear  Nunc 
Blotting paper Amersham 
Cell culture dishes (75 cm2 flasks, 6/12/24-well plates) Becton Dickinson 
Cellulose nitrate filter, 8 µm Sartorius 
Filter, 0.2 µm Schleicher & Schuell 
miniPERM cell culture module Greiner Bio-One 
NHS-activated Sepharose 4 Fast Flow resin  Amersham 
Nitrocellulose membrane GE Healthcare 
Petri dish  Roth 
Roti-Spin MINI 3 columns Roth 
Self-adhesive film Nunc 
Superdex 75 column Amersham 
 
Software Supplier 
GraphPad Prism 5.01 GraphPad Software 
FASTA online sequence comparison service University of Virginia 
MagicScan32 V4.5 Umax 
MicroWin 2000 Berthold Technologies 
MS Office Microsoft 
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Multicalc program PerkinElmer 
PeptideCutter 
Swiss Institute of Bioinfor-
matics 
RasMol Version 2.4.7.2 RasWin Molecular Graphics 
Redasoft Visual Cloning 2000 v.1.0 Redasoft 
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IV. Primers 5’  3’, ordered from Invitrogen (DNA oligos, 25 nmole scale, 
desalted) 
hGH-fwd CAC CAT GGC TAC AGG CTC CCG 
hGH-rev CTA GAA GCC ACA GCT GCC C 
R77C-fwd CCA ACC TAG AGC TGC TCT GCA TC 
R77C-rev GAT GCA GAG CAG CTC TAG GTT GGA T 
D112G-fwd ACA GCA ACG TCT ATG GCC TCC TA 
D112G-rev TAG GTC CTT TAG GAG GCC ATA GA 
C182A-rev CTA GAA GCC ACA GCT GCC CTC CAC AGA GCG AGC CTG CA 
C189A-rev CTA GAA GCC AGC GCT GCC CTC 
Δ188-190-rev CTA GAA GCC CTC CAC AGA GCG GCA CTG CA 
T7 (fwd) TAA TAC GAC TCA CTA TAG GG 
BGH-rev TAG AAG GCA CAG TCG AGG 
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V. pcDNA3.1-GH (wt) sequence: recognition sequences for T7 (precedes 
insert) & BGH-rev (after insert) are in italics and underlined, insert is 
bolded and the signal sequence is in addition underlined. CACC right 
before the signal sequence is necessary for directional TOPO cloning. 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCAT
AGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTT
AAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTG
CGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGT
AATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAA
ATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCA
TAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACT
TGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC
CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTAT
TAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG
ACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATC
AACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTAC
GGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCG
AAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGTTAAGCTTGGTACCGAGCTCGGATC
CAGTACCCTTCACCATGGCTACAGGCTCCCGGACGTCCCTGCTCCTGGCTTTTGGCCTGCTCTGCC
TGCCCTGGCTTCAAGAGGGCAGTGCCTTCCCAACCATTCCCTTATCCAGGCTTTTTGACAACGCTA
TGCTCCGCGCCCATCGTCTGCACCAGCTGGCCTTTGACACCTACCAGGAGTTTGAAGAAGCCTATA
TCCCAAAGGAACAGAAGTATTCATTCCTGCAGAACCCCCAGACCTCCCTCTGTTTCTCAGAGTCTA
TTCCGACACCCTCCAACAGGGAGGAAACACAACAGAAATCCAACCTAGAGCTGCTCCGCATCTCCC
TGCTGCTCATCCAGTCGTGGCTGGAGCCCGTGCAGTTCCTCAGGAGTGTCTTCGCCAACAGCCTGG
TGTACGGCGCCTCTGACAGCAACGTCTATGACCTCCTAAAGGACCTAGAGGAAGGCATCCAAACGC
TGATGGGGAGGCTGGAAGATGGCAGCCCCCGGACTGGGCAGATCTTCAAGCAGACCTACAGCAAGT
TCGACACAAACTCACACAACGATGACGCACTACTCAAGAACTACGGGCTGCTCTACTGCTTCAGGA
AGGACATGGACAAGGTCGAGACATTCCTGCGCATCGTGCAGTGCCGCTCTGTGGAGGGCAGCTGTG
GCTTCTAGAAGGGTCAAGACAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGG
GCCCGCGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTC
ATCATCACCATCACCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGC
CATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTT
CCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGG
TGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCT
CTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCG
GCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAG
CGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTC
TAAATCGGGGCATCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTG
ATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGG
AGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCT
ATTCTTTTGATTTATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAAC
AAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTC
CCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCC
CAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGC
CCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGAC
TAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAG
GAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGAT
CTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTC
CGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATG
CCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTG
CCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCG
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CAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGC
AGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGC
GGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAG
CACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCG
CGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCC
ATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTG
GCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGC
TTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCA
TCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGCGAAATGACCGAC
CAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGC
TTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTC
TTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAAT
TTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT
TATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCT
GTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCC
TGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCG
GGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATT
GGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTA
TCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG
TGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG
CTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA
CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCG
CTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGT
AGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAG
CCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCG
CCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTC
TTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAG
CCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGT
GGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATC
TTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTA
TCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATA
TATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGT
CTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA
CCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCA
ATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAG
TCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTT
GCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCC
CAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCT
CCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAAT
TCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTC
TGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCA
CATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATC
TTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTT
ACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG
GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGC
ACATTTCCCCGAAAAGTGCCACCTGACGTC 
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VI. Binding epitopes of in-house mAbs [Wu, 1998]. Bindungstelle is Ger-
man for binding site.  
 
Epitop des Mab 6C1
Tabelle: Kreuzreaktion mit hGH Varianten und Fragmenten
hGH Varianten hGH Fragmente
rhGH         100.00% 
met-hGH         n.d.                 
des 1           n.d.     
des 4         11.76%      
des 7          1.42% 
des 13        <0.01% 
clip 1         7.80% 
clip 2         9.70% 
hPL           <0.10% 
20 kD        80.00% 
hGH CV        <0.10% 
NIH hGH       60.00% 
hGH hybrid      n.d.
1-43            n.d. 
1-134   1.42%                  
15-125        <0.05%       
20-41         <0.01%     
95-134        <0.05% 
126-170       <0.01% 
135-191       <0.01% 
141-191       <0.01% 
 
 
 
 
*n.d.= nicht untersucht
Ka: 1,7X109 1/Mol 
Subklasse: IgG 1 
An Receptor-Bindungsstelle 2
NH
COOH
F1
P5
E33
L75
S105
R183
D154
L129
F191
V96
2
Bindungsstelle 2
Bindungsstelle 1
Mab 6C1
 
 
Epitop des Mab 7B11
Tabelle: Kreuzreaktion mit hGH Varianten und Fragmenten
hGH Varianten hGH Fragmente
rhGH         100.00% 
met-hGH         n.d.                 
des 1           n.d.     
des 4         <0.01%      
des 7         <0.01% 
des 13        <0.01% 
clip 1        76.20% 
clip 2        29.10% 
hPL            0.94% 
20 kD         45.70% 
hGH CV        22.90% 
NIH hGH       53.30% 
hGH hybrid      n.d.
1-43            n.d. 
1-134 22.55%                  
15-125         0.84%       
20-41         <0.01%     
95-134        <0.01% 
126-170       <0.01% 
135-191        <0.1% 
141-191       <0.01% 
 
 
 
 
*n.d.= nicht untersucht
Ka: 3,0X109 1/Mol 
Subklasse: IgG 1 
An Rezeptor-Bindungsstelle 2
NH
COOH
F1
P5
E3 3
L 7 5
S1 0 5
R18 3
D1 5 4
L1 2 9
F1 9 1
V 96
2
Bindungsstelle 2
Bindungsstelle 1
Mab 7B11
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Epitop des Mab 8B11
Tabelle: Kreuzreaktion mit hGH Varianten und Fragmenten
hGH Varianten hGH Fragmente
rhGH         100.00% 
met-hGH         n.d.                
des 1           n.d.     
des 4           n.d.    
des 7         16.70% 
des 13         3.01% 
clip 1        46.79% 
clip 2       105.13% 
hPL            0.63% 
20 kD         36.54% 
hGH CV          n.d. 
NIH hGH       64.10% 
hGH hybrid      n.d.
1-43          <0.01% 
1-134          0.71%                  
15-125         0.01%       
20-41         <0.01%     
95-134         0.03% 
126-170       <0.01% 
135-191       <0.01% 
141-191         n.d. 
 
 
 
 
*n.d.= nicht untersucht
Ka: 7,0X109 1/Mol 
Subklasse: IgG 1 
An Rezeptor-Bindungsstelle 1
NH
COOH
F1
P5
E3 3
L 7 5
S1 0 5
R18 3
D1 5 4
L1 2 9
F1 9 1
V 96
2
Bindungsstelle 2
Bindungsstelle 1
Mab 8B11
 
 
Epitop des Mab 10A7
Tabelle: Kreuzreaktion mit hGH Varianten und Fragmenten
hGH Varianten hGH Fragmente
rhGH         100.00% 
met-hGH         n.d.                  
des 1         18.60%       
des 4           n.d.    
des 7         44.38% 
des 13        14.20% 
clip 1        37.14% 
clip 2         9.51% 
hPL           <0.01% 
20 kD          0.20% 
hGH CV        11.11% 
NIH hGH       70.18% 
hGH hybrid      n.d.    
1-43            n.d. 
1-134  0.94%                  
15-125         0.05%       
20-41         <0.01%     
95-134         0.01% 
126-170       <0.01% 
135-191       <0.01% 
141-191         n.d. 
 
 
 
 
*n.d.= nicht untersucht
Ka: 9,4X109 1/Mol 
Subklasse: IgG 1 
An Rezeptor-Bindungsstelle: keine
NH
COOH
F1
P5
E33
L75
S105
R183
D154
L129
F191
V96
2
Bindungsstelle 2
Bindungsstelle 1
Mab 10A7
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VII. DNA Ladders [Invitrogen]. 0.5 µl Low DNA Mass Ladder contains 
following amounts of DNA per band: 2000 bp/25 ng, 1200 bp/15 ng, 800 
bp/10 ng, 400 bp/5 ng, 200 bp/2.5 ng, 100 bp/1.25 ng. 
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